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ABSTRACT 
  To grow beyond 1-2 mm in size, a tumour needs to establish an independent blood 
supply to sustain an ever-increasing demand for oxygen and nutrients. This requirement is 
fulfilled through the production of several pro-angiogenic growth factors, eventually leading 
to accelerated neo-vessel formation. While numerous pro-angiogenic factors have been 
characterized so far, Vascular Endothelial Growth Factor A, (VEGF-A) has been identified as 
a predominant regulator of tumour angiogenesis by facilitating endothelial cell (EC) 
migration, proliferation, tube formation, and survival. VEGF-A gene structure and function 
have been extensively elucidated over last decades. Notwithstanding, due to conflicting 
results both in experimental and clinical settings, VEGF-A contribution to tumour progression 
is  still  debated.  Some  controversies  arise  due  to  the  fact  that  most  of  the  studies  have  
underestimated the impact of VEGF-A gene alternative splicing, which eventually gives rise 
to several splicing isoforms. In keeping with this possibility, we previously demonstrated that 
the two most abundant VEGF-A splicing isoforms (VEGF165 and  VEGF121) have different 
biological effects in vivo. In particular, we showed that both isoforms are equally able to 
activate the local endothelium, eventually leading to capillary sprouting, but only the longer 
isoform, VEGF165, is also able to promote full vessel maturation. This ability can be ascribed 
to  the  capacity  of  VEGF165, but not VEGF121, to recruit a peculiar population of accessory 
myeloid cells, which sustains vessel maturation. We termed these cells Nrp-1 Expressing 
Mononuclear cells (NEMs) as they express Neuropilin-1 (Nrp-1), a non-tyrosine kinase co-
receptor crucially involved in their mobilization. 
  Hence, our data strongly point towards a differential contribution of VEGF-A splicing 
isoforms to tumour angiogenesis. Based on these findings, we investigated the impact of 
VEGF165 and VEGF121 on tumour angiogenesis and progression in human tumour samples. 
  To assess the relevance of VEGF-A splicing in the context of human malignancies, we 
first quantified the relative abundance of VEGF165 and VEGF121 in a set of colorectal cancer 
patients.  The  ratio  of  isoform  expression  (VEGF165/VEGF121) was analysed both in tumour 
mass and in a matched sample of healthy mucosa, harvested at least 10 cm far from the 
tumour site.  
  The  VEGF  isoform  ratios  were  not  statistically  different  in  mucosa  and  tumour.  
Similarly, no correlation with Grading (G), Stage (T), or Vascular Extra-Parietal Invasion 
(IVEP) was detected. However, the VEGF165/VEGF121 ratio was significantly higher in 
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tumours derived from patients with metastatic disease, arguing for a facilitating role of 
VEGF165 in hematogenous tumour dissemination. 
  Despite the absence of any obvious trend in VEGF-A splicing regulation, the 
VEGF165/VEGF121 ratio showed a significant degree of variability. We thus further analyzed a 
restricted group of patients who strongly up-regulated VEGF165 (VEGF165high patients). 
Interestingly, these patients showed reduced lymph node infiltration but improved vessel 
morphology.  
  In accordance with the above information, tumours that strongly up-regulated 
Semaphorin3A (Sema3A - known Nrp-1 ligand and NEM recruiter) showed improved vessel 
structure and better outcome (no metastasis, no lymph node infiltration and longer survival).  
  Taken  together,  these  data  suggest  that  two  major  Nrp-1  ligands,  VEGF165 (but not 
VEGF121) and Sema3A, are able to enhance vessel maturation in tumours, possibly through 
the recruitment of NEMs. This evidence is consistent with the conclusion that improved 
tumour vascular function is detrimental for tumour growth, in concert with a number of recent 
reports highlighting the role of vessel normalization in tumour progression. According to this 
notion, high levels of either VEGF165 or Sema3A correlated with better disease outcome, as 
evaluated by lymph node infiltration and overall survival. Of interest, however, up-regulation 
of VEGF165 was not associated with a reduced metastatic spread (as Sema3A did), while, on 
the contrary, higher levels of VEGF165 were found in patients with metastatic disease. Taken 
together, these data appear fully consistent with recently published information supporting the 
concept that the vascular normalization induced by anti-angiogenic therapies indeed elicits 
tumour cell spreading and metastasis.  
  Our additional studies on human specimens and cell culture identified hypoxia as a 
crucial regulator of VEGF splicing. Ongoing experiments to further elucidate the effect of 
other environmental factors on the regulation of VEGF splicing balance is in progress.   
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1. INTRODUCTION 
1.1 Physiological and pathological aspects of angiogenesis 
Angiogenesis is the process of creating new blood vessels from the pre-existing 
vasculature. It is an intricate but tightly orchestrated series of events, that always begins with 
the proliferation of resident endothelial cells (ECs), mainly triggered by the local production of 
secreted pro-angiogenic factors. Then, newly generated ECs organize in 3D structures which 
eventually evolve into mature vessel tubes. Full vessel maturation involves lumen formation 
and the coverage of ECs with mural cells (typically pericytes and smooth muscles cells), a key 
event in the stabilization of newly formed blood vessels. This highly organized process has 
been the focus of a large body of studies, specifically due to its importance in development, 
tissue maintenance and survival, as well as in a wide range of human diseases. During last 
three decades, intensive research has obtained a large body of knowledge regarding both 
activators and inhibitors of angiogenesis. Physiological angiogenesis, as a crucial process 
during embryonic development, happens in adulthood only during wound healing, skeletal 
growth, menstrual cycle (Smith, 2001; Torry and Torry, 1997), and pregnancy. It occurs also 
in a wide range of diseases including intraocular neovascular disorders, immunogenic 
rheumatoid arthritis, psoriasis, and tumourigenesis. In addition, angiogenesis plays an essential 
role in tumour growth, invasion, and metastasis (Folkman et al., 1989). Under both 
physiological and pathological angiogenesis, a cascade of highly coordinated cellular activities 
leads to the establishment of new blood vessels in response to increased requirement for 
oxygen and nutrients (Figure 1).  
A tumour mass cannot grow beyond 2-3 mm3 without  angiogenesis.  Indeed,  when  a  
tumour grows up to 1-2 mm in diameter, its demand for oxygen and nutrients exceeds the local 
supply. This results in a hypoxic microenvironment that consequently cooperates with other 
oncogenic stresses to induce angiogenesis. Neovascularization provides the primary tumour 
with additional supply of nutrients and oxygen and promotes the dissemination of the tumour 
cells to distant organs.  
Most of the solid tumours do not have an intrinsic angiogenic capability, thus they 
traverse two phases of growth: an avascular phase followed by a vascular phase in which new 
capillaries penetrate the tumour resulting in its growth and progression. Since tumour 
progression occurs after extended periods of non-neovascularized tumour dormancy, the 
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existence of an “angiogenic switch” was speculated as a requirement for this to happen. This 
switch involves more than simple up-regulation of pro-angiogenic factors and seems to be the 
result of balance between positive and negative regulators. Tumour growth requires disruption 
of this balance. A wide range of factors contribute to this switch, including progenitor 
endothelial cells (PECs), crosstalk between angiogenic stimulators and their receptors, and the 
interplay between vasculogenesis and lymphangiogenesis. 
 Increased angiogenic capacity is mostly observed long before any morphological 
manifestation of neoplastic transformation (Brem et al., 1977; Gimbrone and Gullino, 1976a, 
b). In this regard, angiogenesis might be considered as an early marker of neoplastic 
transformation.  
Introduction 
??
?
 
 
 
????(Chung?et?al.,?2010)?
Figure?1.?Physiological?and?pathological?angiogenesis.?a)?During?physiological?angiogenesis,?various?stimuli? (such? as? hypoxia)? induce? an? organized? sequence? of? events? that? constitutes? the? angiogenesis?cascade.? In? the?phase?of? initiation,?an? increase? in?growth? factors?such?as?VEGF-A?and? fibroblast?growth?factor?(FGF)?derived?from?endothelial?cells?leads?to?vessel?destabilization?and?initiation?of?vessel?sprouting?and?endothelial?cell?proliferation.?Matrix?metalloproteinases?(MMPs)?facilitate?extracellular?matrix?(ECM)?remodelling? and? increase? the? bioavailability? of? ECM-sequestered? growth? factors.?When? new? vessels?establish,?blood?perfusion? takes?place?and,? concomitantly,? levels? of?VEGF?decline;? the? resolution?phase?begins? coincident?with? an? increase? in? platelet-derived? growth? factor? (PDGF),? angiopoietins? (Ang),? and?transforming?growth?factor-???expression?responsible?for?the?recruitment?and?subsequent?stabilization?of?mural?cells?and?vascular?smooth?muscle?cells?around?the?nascent?vessel.?b)?Under?pathological?conditions,?tumour-?secreted?VEGF-A?triggers?the?angiogenesis?cascade.?Tumour?cells?lead?to?increased?expression?of?soluble?factors?also?responsible?for?activating?resident?fibroblasts?and?for?infiltrating?immune?cells.?Such?stromal? cell? types?are?able? to? sustain? the?angiogenic?process?via? the? secretion?of?vascular?growth-?and?inflammation-promoting?elements.?GDSF,?granulocyte?colony?stimulating?factor;?IL-1???interleukin-1????
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1.2 Colorectal Carcinoma 
Cancer of the large bowel (also known as colorectal cancer) is one of the leading 
causes of cancer mortality worldwide. Colorectal cancer (CRC) is the third most frequently 
diagnosed cancer in men and women and the second cause of cancer-related death in the 
United States and other developed countries but occurs much less frequently in the 
developing world. It had been estimated that 141,210 men and women (71,850 men and 
69,360 women) were diagnosed with and 49,380 men and women would die of colorectal 
carcinoma in 2011 (NCI’s SEER Cancer Statistics Review). Despite all recent advances in the 
management of CRC, there is a strong need for more efficient and well-tolerated anti-cancer 
drugs. Colorectal carcinoma, similar to other sorts of cancers, requires angiogenesis to grow 
beyond few millimetres. The fact that tumour progression and metastasis is dependent on 
blood  vessels  makes  angiogenesis  a  putative  target  for  therapy.  In  this  regard,  one  of  the  
known pathways contributing to this process is the vascular endothelial growth factor (VEGF) 
and its receptors.    
 
1.3 Vascular Endothelial Growth Factors 
The VEGF gene family consists of various members, which include VEGF-A, -B, -C, 
-D, -E, PlGF, and snake venom-derived VEGFs (Dvorak, 2002; Hicklin and Ellis, 2005). The 
best characterized among all VEGF family members is VEGF-A. Vascular endothelial growth 
factor A or VEGF-A (commonly referred to as VEGF), is a potent mitogen involved in 
mitogenesis, angiogenesis, endothelial survival as well as the induction of hematopoiesis 
(Kowanetz and Ferrara, 2006). VEGF is encoded by a single gene located on chromosome 6 
in humans and consists of eight exons (Harper and Bates, 2008). It plays a crucial role in the 
morphogenesis, differentiation, and stability of vessels by regulating the proliferation, 
migration and persistence of ECs (Lamalice et al., 2007). It also contributes to vasculogenesis 
and lymphangiogenesis during embryonic development (Shibuya and Claesson-Welsh, 2006).  
The need for VEGF-A signalling during early vasculogenesis/angiogenesis has been 
emphasized by the observation that mice lacking a single VEGF-A allele die at about 
embryonic day 9.5 (Carmeliet et al., 1996; Ferrara et al., 1996), indicating a dose-dependent 
regulation of embryonic vessel development by VEGF. In 1989, Napoleone Ferrara purified 
this protein from bovine pituitary follicular cell conditioned media as a potent endothelial 
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mitogen (Ferrara and Henzel, 1989). Interestingly, the same polypeptide had been previously 
isolated as vascular permeability factor in 1983 (Senger et al., 1983). In fact, the cloning of 
VEGF  was  a  great  milestone  in  understanding  the  process  of  angiogenesis.  Besides  its  
multiple roles in several facets of vessel formation, both during development and in 
adulthood, it was more recently found to be an important trophic factor for a disparate variety 
of cell types, most notably neuronal cells (Carmeliet and Storkebaum, 2002).  
Importantly, its role as a key mediator of tumour angiogenesis is now well established 
and has been long considered a therapeutically addressable bottle-neck for tumour growth. 
This has led to decades of debates on the efficacy of anti-VEGF cancer therapy that 
eventually came to an end with the approval of the first anti-angiogenic agent, bevacizumab, 
an anti-VEGF monoclonal antibody, by the U.S. Food and Drug Administration (FDA) in 
2004, with an indication for the treatment of some types of refractory CRCs. A debate on the 
therapeutic usefulness of bevacizumab has been rejuvenated by recent discoveries shedding 
shadows on the clinical benefits of VEGF inhibitors, as discussed later in the text (Ebos et al., 
2009; Paez-Ribes et al., 2009). In fact, most of the human cancer cells express VEGF-A, and 
its major receptor (VEGFR-2) is also highly expressed by ECs involved in tumour 
angiogenesis (Kerbel, 2008). Furthermore, VEGF-A is also secreted by tumour stromal cells 
such as fibroblasts, monocytes, and platelets (Kut et al., 2007). 
All members of VEGF family have been shown to possess angiogenic capacity, 
although at dissimilar degree (Harper and Moses, 2006). VEGF-B, which only binds VEGF 
Receptor-1 (VEGFR-1), has been long considered non-angiogenic and a mere “tuning” factor 
for VEGF-A (Hirashima et al., 2003). VEGF-C and VEGF-D that bind mainly VEGF 
Receptor-3 are primarily lymphangiogenic factors (Alitalo et al., 2005). Conversely, the role 
of PlGF (Placental-derived Growth Factor) is far more ambiguous and apparently affects 
different aspects of angiogenesis (Bais et al., 2010; Luttun et al., 2002). 
1.3.1 Structure of VEGF 
VEGF-A, as the best-characterized member of the VEGF family, is a homodimeric 
glycoprotein comprised of two identical 23 KDa subunits. Among several alternatively 
spliced isoforms of human VEGF-A, VEGF165, as a heparin-binding homodimeric 
glycoprotein of approximately 45 KDa (Leung et al., 1989), has been considered as the most 
abundant  and  mitogenic  isoform  of  this  group.  Other  important  isoforms  of  VEGF-A,  
including VEGF121, VEGF189, and VEGF206 originated from alternative splicing of VEGF-A 
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gene,  which  consists  of  eight  exons  (Neufeld  et  al.,  1999).  The  longer  VEGFs  such  as  
VEGF189 and  VEGF206 bind heparin in the extracellular matrix, while the lack of basic 
residues in exon 6 and 7 in VEGF121, results in the loss of extracellular matrix segregation 
(Houck et al., 1992). Indeed, a large body of evidence indicates that the heparin-binding 
VEGF-A isoforms play  an  essential  role  in  the  initiation  of  vascular  branching  (Gerhardt  et  
al., 2003; Ruhrberg et al., 2002). In addition, VEGF165, which lacks exon 6, exists in both 
bound and freely diffusible protein (Neufeld et al., 1999). Besides being variable in 
bioavailability  and  bioactivity,  isoforms  of  VEGF  show  different  receptor  specificities.  For  
instance, VEGF165, via exon 7-encoded domains, binds to tyrosine kinase receptors 
VEGFR1/Flt1 and VEGFR2/Flk1, also neuropilin-1 (NRP-1) and NRP-2 (Ferrara et al., 2003; 
Olsson et al., 2006).  
1.3.2 Alternatively Spliced Isoforms of the VEGF-A pre-mRNA 
As briefly introduced in the previous Chapter, the VEGF mRNA undergoes alternative 
splicing to give rise to various isoforms (Houck et al., 1991). The VEGF gene consists of 8 
exons and encompasses nearly 14 Kbp (Figure 2). Basal transcription is driven by a TATA-
less promoter, specifically tuned by diverse stimuli, among which hypoxia is worth 
mentioning (Giacca, 2010). At least seven protein isoforms are produced by translation of 
various mRNAs subjected to alternative splicing of the native human VEGF-A pre-mRNA 
(Tischer et al., 1991) composed of 206, 189, 183, 165, 148, 145, and 121 amino acids (aa) 
after the removal of the signal peptide.  All VEGF isoforms are secreted as covalently linked 
homodimers.  The  three  most  abundant  isoforms  detected  so  far  in  vivo  are  VEGF121, 
VEGF165, and VEGF189.  
All the mRNAs coding for the various isoforms contain exons 1 to 5 in their 5? regions 
and are characterized by different combinations of exons 6, 7, and 8, or a portion of these, in 
their 3? regions.  In VEGF-A121, exon 5 is spliced to the 6 aa-encoding exon 8. In the mRNA 
coding for VEGF-A165, the whole exon 7 is included between exon 5 and exon 8, while in the 
case of VEGF148, the 5? part of exon 7 (7a) is spliced to exon 8, generating an open reading 
frame that terminates protein translation in exon 8 by the inclusion of an additional single 
amino acid, as schematically shown in Figure 2. The mRNA isoforms coding for VEGF-A206, 
VEGF-A189 and VEGF-A183 include complete exon 6 (coding for 41 amino acids) or parts of 
exon 6 shorter at their C-terminus. The coding mRNA for the longest VEGF-A isoform 
(VEGF-A206) contains whole exon 6, while mRNAs coding for VEGF-A189 and VEGF-A183 
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are generated using alternative 5? donor sites that reduce the coding region to 24 aa (exon 6a) 
and 18aa (exon 6a?) respectively. Only VEGF-A145 contains exon 6a inserted between exon 5 
and 7. A 1881 bp-long 3?UTR ends the transcripts, containing multiple alternative 
polyadenylation signals. This region also includes a number of AU-rich elements (AREs) 
shown to be involved in the regulation of mRNA stability under hypoxic conditions (Paulding 
and Czyzyk-Krzeska, 2000).  
Additional variability is generated when a 3? splice site distal to that typically used by 
exon 8 is utilized. This specifies a shorter exon (exon 8b), the 5? of which codes for 6 amino 
acids different from classic exon 8. This distal splice site choice can occur combined with 
exon 6 or 7 inclusion or exclusion, resulting in the generation of a family of polypeptides 
differing from the above-mentioned isoforms by the last six amino acids. The most prominent 
of these polypeptides is VEGF-A165b. Interestingly, it has been shown that the protein 
isoforms encoded by these exon 8b-containing mRNAs have inhibitory potential rather than 
stimulatory effects on the VEGF receptors (Harper and Bates, 2008).  
The N-terminal portion of VEGF-A, encoded by exons 1-5, is sufficient to bind and 
activate the typical VEGF receptors. As a consequence, all the VEGF-A splicing isoforms can 
interact with VEGFR-2 and with a 10-fold higher affinity with VEGFR-1 (Ferrara et al., 
2003). Instead, exons 6 and 7 at the C-terminus of the protein are essential in specifying its 
bioavailability and biodistribution. Particularly, the 24 aa- and 44 aa- stretches encoded by 
exons 6a and 7 are highly enriched in clusters of basic amino acids, creating the capacity to 
bind negatively charged heparin (heparin binding domains, HBDs). These HBDs determine 
the capacity to bind cell surface and extracellular matrix heparan sulfate proteoglycans 
(HSPGs) and thus crucially modulate their localization in the extracellular matrix. Various 
VEGF isoforms distribute in the environment of a VEGF-secreting cell, depending on the 
presence or absence of the heparin-binding domain (Ferrara et al., 2003). It has been 
suggested that the differential localization of VEGF isoforms in the extracellular matrix might 
regulate vascular branching pattern (Ruhrberg et al., 2002). VEGF-A121,  as  the  shortest  
isoform, lacks any HBD and is weakly acidic. According to these characteristics, it is freely 
diffusible.  In  contrast,  VEGF-A189 and  VEGF-A206 have  two  HBDs  and  are  kept  in  the  
extracellular matrix and on the cell surface. VEGF-A165, the most abundant isoform (Ferrara 
and Davis-Smyth, 1997), differs from VEGF-A121 only by the inclusion of exon 7. Its 
moderate affinity for heparin enables this isoform to be present as a soluble and a cell-bound 
factor (Krilleke et al., 2009). The functional significance of these HBDs remain elusive, but it 
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has been reasonably proposed that binding to the extracellular matrix allows the HBD-
containing VEGF-A isoforms to form a concentration gradient that extends from the ischemic 
areas which is crucial for proper angiogenic stimulation (Oshikawa et al., 2010).  
Differential effects of VEGF165 and  VEGF121 isoforms  were  correlated  with  their  
differential capacity to recruit, to the sites of neoangiogenesis, a novel population of CD11b+, 
Gr-1- circulating cells deriving from bone marrow and expressing the Nrp-1 receptor. It has 
been demonstrated that VEGF165 acts as a potent chemoattractor for these Nrp-1 expressing 
mononuclear (NEM) cells, while VEGF121 fails to do so. In addition, it has been observed that 
NEMs play an important role by secreting PDGF-B, TGF-beta and other chemokines active in 
promoting vessel maturation, which in turn results in a higher degree of ?-SMA+/NG2+ 
mural cell coverage and decreased vascular leakiness (Zacchigna et al., 2008). Altogether, it 
is strongly suggested that VEGF-A121 is sufficient neither for normal vasculogenesis in the 
embryo development nor for adult angiogenesis and it is not only because of its incapability 
to determine a concentration gradient through HSPG binding, but also due to its failure in 
inducing peri-endothelial cell recruitment, vessel maturation and arterial specification through 
NEM recruitment via exon 7-mediated NRP-1 binding (Zacchigna et al., 2008). On the other 
hand, the regulatory role of the VEGF-A isoforms consisting of exon 8b requires further 
investigation.  For instance, VEGF-A165b differs from VEGF-A165 only in the C-terminal six 
amino acids, which gives this protein the ability of having only a weak stimulatory activity 
(Bates  et  al.,  2002).  VEGF-A165b still binds VEGF receptors with equal affinity as other 
VEGF-A ligands, however is a poor ligand of VEGFR-2, specifying a distinct tyrosine 
phosphorylation pattern, and fails to bind HSPGs and to interact with NRP-1, in a similar way 
as in the case of VEGF-A121. Therefore, VEGF-A165b may act competitively with other VEGF 
isoforms and suppress their angiogenic activity (Woolard et al., 2004). 
Collectively, it is now clear that different VEGF isoforms have dissimilar biological 
functions in vivo, and this is highly valuable to fully understand the elaborate activity of 
VEGF-A during physiological and pathological angiogenesis. Indeed, its angiogenic capacity 
has been long studied and is now well established, but the inability to translate experimental 
models to the clinic might suggest the existence of more complex, still obscure tuning of 
VEGF biological activity (Carmeliet and Jain, 2011). As discussed later in this thesis, VEGF 
alternative splicing might represent a poorly investigated mechanism partially able to justify 
such an unresolved complexity. 
 
Introduction 
??
?
? ? ? ? ? ? ? ? ? ????????????(Ladomery?et?al.,?2007) 
Figure?2.?Exon?structure?of?the?VEGF?gene.?
 
1.3.3 Family of VEGF receptors 
During the early 1990s, human VEGF receptors were structurally identified by cDNA 
cloning (Millauer et al., 1993; Pajusola et al., 1992; Shibuya et al., 1990; Terman et al., 1991). 
VEGF receptors were originally characterized on the surface of vascular endothelial cells, and 
for  many  years  it  was  believed  that  their  expression  was  restricted  to  endothelial  and  peri-
endothelial compartment (Ferrara, 2002). It was subsequently shown that VEGFRs exist also 
on bone marrow-derived cells such as monocytes (Shen et al., 1993) and on a large variety of 
other cell types in the body. VEGF binds two receptor tyrosine kinases (RTKs), VEGFR-1 
and VEGFR-2, which are highly homologues. VEGFR-1(Flt-1) and VEGFR-2 (Flk-1/KDR) 
both have seven Ig-like domains in the extracellular region, a single-transmembrane area, and 
a consensus tyrosine kinase sequence (Terman et al., 1991) interrupted by a kinase insert 
domain and are activated by ligand-triggered dimerization (Matthews et al., 1991). VEGFRs, 
upon ligand binding, dimerize and induce mitogen-activated protein kinase (MAPK), 
phosphoinositide-3 kinase and other pathways involved in the function of endothelial cells 
(Ferrara et al., 2003). In response to ligand binding, VEGF receptor tyrosine kinases activate a 
series of separate downstream signalling pathways (Kowanetz and Ferrara, 2006).  
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Similar to Vegfa+/- mice, Vegfr2- null mice display early embryonic lethality and 
severe vascular defects (Shalaby et al., 1995), underscoring the pivotal role of this receptor in 
VEGF-A signalling. Whereas a large body of evidence suggests that VEGFR-2 is the key 
receptor for VEGF-A-induced endothelial cell responses such as mitogenesis and vascular 
permeability, the role of VEGFR-1 is more intricate (Shibuya, 2006). Through sequestration 
of VEGF-A, VEGFR-1 can adversely regulate VEGFR-2 signalling (Hiratsuka et al., 1998; 
Park et al., 1994). It can also promote monocyte migration (Barleon et al., 1996), endothelial 
cell secretion of proteases (Hiratsuka et al., 2002) and growth factors (LeCouter et al., 2003), 
the growth of specific cancer cells overexpressing this receptor (Lichtenberger et al., 2010; 
Wu et al., 2006), and sustain myocardial function after infarction and heart failure 
(Lahteenvuo et al., 2009; Zentilin et al., 2010), underpinning the limitations of the 
conventional  outlook  that  put  toward  VEGFR-1  as  a  simple  decoy  receptor  for  VEGF-A.  
Another member of the same family of RTKs is VEGFR-3 (Flt-4), which is not a receptor for 
VEGF-A, but instead for VEGF-C and VEGF-D and mainly contributes to 
lymphangiogenesis (Alitalo et al., 2005). 
1.3.3.1 VEGFR-1 (Flt-1) 
More than a decade ago, VEGFR-1 was the first receptor tyrosine kinase (RTK) 
identified as a VEGFR (de Vries et al., 1992). VEGFR-1 functions and signalling features 
may vary depending on the developmental stage and the cell type. Interestingly, expression of 
VEGFR-1 is up-regulated by hypoxia via a HIF-1-dependent mechanism (Gerber et al., 
1997), suggesting an independent role in VEGF signalling under stress conditions.  
VEGFR-1 binds different members of the VEGF family, namely VEGF-A, VEGF-B, 
and PlGF (Ferrara, 2004) (Figure 3). It has been long considered as a simple “decoy” 
receptor, able to weaken VEGF-A signalling, competing for its binding with VEGFR-2, 
which in turn was considered the proper VEGF-A receptor. In this respect, it has been shown 
that an alternatively spliced soluble form of VEGFR-1 (sFlt-1) is an inhibitor of VEGF 
activity, through the seizure of circulating VEGF-A (Hiratsuka et al., 1998). Indeed, Flt-1 has 
a strong affinity for its ligand; in detail, the ability of binding VEGF and PlGF has been 
referred to the second Ig-like domain of this receptor (Christinger et al., 2004). Despite this 
strong affinity, Flt-1 shows a weak tyrosine autophosphorylation activity in response to 
VEGF-A. However, it has been more recently demonstrated that VEGFR-1 can interact with 
different signal-transducing proteins and generate a mitogenic signal (Maru et al., 1998). In 
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addition, it has been suggested that a crucial function of VEGFR-1 signalling in the vascular 
endothelium is not the control of angiogenesis but, rather, the paracrine secretion of tissue-
specific growth factors (Zhang et al., 2009). 
1.3.3.2 VEGFR-2 (KDR, human; Flk-1, mouse) 
VEGFR-2 has been primarily found on endothelial cells, where it mediates all major 
angiogenic effects of VEGF-A, but it has also been detected on a subset of multipotent human 
hematopoietic stem cells (HSCs) (Kabrun et al., 1997). During early embryogenesis, VEGFR-
2 is highly expressed in vascular endothelial progenitors, whereas in later stages of 
vasculogenesis, VEGFR-2 expression decreases. However, under the conditions of 
pathological angiogenesis such as in tumours, its expression is upregulated (Matsumoto and 
Claesson-Welsh, 2001). Among the most important functions of VEGFR-2, are the 
stimulation of vascular endothelial cell survival and growth, in addition to the promotion of 
angiogenesis. Indeed, VEGFR-2 is the key mediator of the mitogenic, angiogenic, and 
permeability-enhancing roles of VEGF-A (Ferrara et al., 2003). The VEGFR-2 binding sites 
have been located in the second and third Ig-like domains. Dimerization and ligand-dependent 
tyrosine phosphorylation gives rise to its mitogenic, chemotactic signalling. Activation of 
VEGFR-2 results in endothelial cell growth through stimulation of the Raf-Mek-Erk pathway.  
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 (Ruiz?de?Almodovar?et?al.,?2009),?modified?
?
Figure.?3.?Family?members?of?VEGF? and? their? receptors.?A)?Mammalian?VEGF? family?members? are?VEGF-A,?-B,?-C,?-D,?and?PlGF.?Among?them,?VEGF-A?binds?to?both?VEGFR1?and?VEGFR2,?whereas?VEGF-B?and?PlGF?only?bind? to?VEGFR-1.?VEGF-C?and?VEGF-D?can?bind? to?VEGFR2?and?VEGFR3.?B)?VEGF-A?may?also?bind?to?heterodimeric?receptor?complexes?formed?by?VEGFR1?and?VEGFR2.?Similarly,?VEGF-C?and?–D?are?able? to?bind?heterodimers? formed?by?VEGFR2?and?VEGFR3.?C)?Neuropilin-1?and? -2? function?as?co-receptors? for? canonical? VEGF-VEGFR? complexes? and? regulate? VEGF? receptor? activation? and? signalling.?Some?splicing?isoforms?of?VEGF-A?bind?to?both?Nrp-1?and?Nrp-2.?Among?family?members?of?VEGF,?VFGF-B?only?binds?to?Nrp-1.??? ? ??
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1.4 Neuropilins 
Neuropilins (NRPs) were initially discovered as neuronal receptors for class III 
semaphorins. There are two neuropilin genes, nrp1 and nrp2. Neuropilins are 130-140 KDa, 
non-tyrosine kinase receptors and have a rather large extracellular domain divided into some 
subdomains, which act as ligand binding sites. Conversely, they consist of a very short 
transmembrane domain, and a short cytoplasmic domain (Neufeld and Kessler, 2008). 
It was later demonstrated that NRP-1 has a role in vascular morphogenesis (Klagsbrun 
et al., 2002; Soker et al., 1998). They are expressed on at least tumour and endothelial cells 
and regulate angiogenesis by acting as receptors for members of the Sema3A and VEGF 
family (Bielenberg et al., 2006; Neufeld and Kessler, 2008). In general, NRP-1 and NRP-2 
are single spanning transmembrane glycoproteins with a crucial role in the development of 
neuronal and vascular systems as receptors for members of class-3 Semaphorin (SEMA3s) 
family of axonal guidance factors and at the same time for members of the vascular 
endothelial growth factor family of angiogenesis factors. NRPs were basically shown to 
contribute to the process of axonal guidance but soon after, it became evident that these 
receptors were also involved in normal blood vessel formation, tumour angiogenesis, and 
tumour progression (Ellis, 2006).  
NRP-1 is able to bind to VEGF165, VEGF-B, VEGF-C, VEGF-D, VEGF-E, PlGF-2, 
HGF,  SEMA3A,  SEMA3B,  and  SEMA3C  while  NRP-2  ligands  are  VEGF165, VEGF145, 
VEGF-C, VEGF-D, HGF, SEMA3B, SEMA3C, and SEMA3F (Kolodkin et al., 1997; 
Sulpice et al., 2008; West et al., 2005). Since the cytoplasmic domain of NRP-1 is short, it is 
thought that its joining to the other signalling proteins is necessary for its bioactivity. The 
ligand binding domains of NRP consist of: (i) an A domain composed of two a-domain 
repeats or two complement binding (CUB) domains (a1a2), (ii) a B domain composed of two 
b-domain repeats or two coagulation factor V/VIII homology- like domains (b1b2), and (iii) a 
C domain or a meprin A5 (MAM) domain that is believed to be important for NRP 
dimerization and the neuropilins’ interaction with other membrane receptors (Chen et al., 
1997; Giger et al., 1998; He and Tessier-Lavigne, 1997) (Figure 4). The B domain of NRP is 
substantial and sufficient for binding of VEGF165 to both NRP1 and NRP2 (Gu et al., 2002). 
However, for NRP-1, simultaneous presence of the A domain enhances VEGF165 binding 
significantly. SEMA3s and VEGF165 both interact with the B domain of NRP-1. The b1 
domain that forms part of the Semaphorin-3A binding domain of NRP-1, is also required for 
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the binding of VEGF165, in addition to the b2 domain, and as a result VEGF165 and Sema3A 
compete for binding to NRP-1 (Gu et al., 2002; Miao et al., 1999; Vander Kooi et al., 2007).  
It  has  been  shown  that  VEGF-A  exon  7  is  crucial  for  NRP  binding  (Soker  et  al.,  
1996). On the other hand, VEGF121,  as  one  of  the  splice  forms  of  VEGF,  differs  from  
VEGF165 by lacking 44 amino acids encoded by VEGF exon 7, which is responsible for 
binding to NRP-1. In this respect, no binding to NRP-1 was detected by VEGF121, although 
recent studies has revealed that VEGF121 can bind NRP-1 (Pan et al., 2007), but comparing 
with VEGF165, VEGF121 is not able to “bridge” NRP-1 and VEGFR-2 (Pan et al., 2007; 
Shraga-Heled et al., 2007). It is likely that the C-terminal residues encoded by exon 8 are 
responsible for the interaction of VEGF121 with NRP-1.  
As already mentioned, Neuropilin-1 (NRP-1) is a unique multifunctional 
transmembrane glycoprotein, a receptor for vascular endothelial growth factor A165 (VEGF-
A165)  and  the  neuronal  guidance  molecule  Semaphorin3A  (SEMA3A)  with  key  roles  in  
vascular and neuronal development. It is worth mentioning that the primary structure of this 
gene is highly conserved within vertebrate species. NRP-1 was first identified in neurons of 
the developing nervous system and considered as a receptor for several class 3 Semaphorins 
as secreted proteins (i.e., Sema3A, Sema3B, Sema3C and Sema3F), which differ in their 
potential to interact with the two neuropilins and are essential for chemorepulsive and growth 
cone collapsing and repulsive signals in vitro (Chen et al., 1997; Feiner et al., 1997; Kolodkin 
et  al.,  1997).  Among  all  members  of  Semaphorin  family, Sema3A binds exclusively to 
neuropilin-1. In NRP-1 the a1 and a2 as well as the b1 domains are required for Sema3A 
binding and signal transduction (Gu et al., 2002; Vander Kooi et al., 2007) (Figure 4). 
  In addition to playing a critical role in the developing nervous systems, NRP-1 is 
expressed in a variety of non-neural cells and can mediate various intercellular signals to 
modulate diverse aspects of physiological and pathophysiologic functions (Banerjee et al., 
2000; Gluzman-Poltorak et al., 2000; Pavelock et al., 2001; Reese et al., 2000; Robert et al., 
2000; Soker et al., 1998). In endothelial cells, NRP-1 enhances the VEGF-A mediated 
biological signals via binding to VEGFR2. It was previously thought that NRPs are not able 
to transduce VEGF signals on their own, and may function only as enhancers of VEGFR2-
mediated VEGF signalling, but recently it has been reported that NRP-1 can transduce VEGF 
signals in the absence of tyrosine kinase VEGF receptors (Wang et al., 2007). 
NRP-1 has also been involved in tumour growth and angiogenesis. In tumour cells, 
which often lack VEGFR-2, it has been supposed that VEGF165 acts as an autocrine survival 
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factor through an NRP-dependent process (Soker et al., 1998). In general, transmembrane 
proteins signal through their cytoplasmic domains, however, in NRPs no signalling motif has 
been detected in their cytoplasmic regions and, consequently, whether and how this domain 
signals is not clear so far. On the other hand, NRP-1 can promote signalling in endothelial 
cells  by  its  intracellular  domain  (Wang  et  al.,  2003).  NRP-1  seems  to  mediate  a  VEGF165/ 
NRP1/ VEGF-2 pathway resulting in tumour growth. Recent studies indicate that the range of 
growth  factors  with  the  ability  of  binding  to  neuropilins  are  not  limited  to  members  of  
Semaphorin and VEGF gene families. Neuropilin-1 functions as a receptor for platelet-
derived growth factor BB (PDGFBB)(Banerjee et al., 2006), transforming growth factor ? 
(TGF?)(Glinka and Prud'homme, 2008), and fibroblast growth factor 2 (FGF2)(West et al., 
2005). Another recently introduced ligand of Nrp-1 is galectin 1, a homodimeric lectin 
expressed in tumour-associated endothelial cells. Binding of galectin 1 to Nrp-1 stimulates 
VEGFR2 phosphorylation and triggers VEGFR2-mediated migration of endothelial cell 
(Hsieh et al., 2008). NRP-1 contains a single serine residue (S612), which can be altered by 
the attachment of a heparan sulphate or chondroitin sulphate glycosaminoglycan. This 
modification has been observed in smooth muscle cells as well as in endothelial cells and 
might modulate responses to VEGF (Shintani et al., 2006). 
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?? ? ? ? ? ? ? ? ? ???(Geretti?et?al.,?2008)?
Figure?4.?Structural?features?and?functions?of?Neuropilin-1?(Nrp-1).?The?a1a2?(pink),?b1b2?(blue),???(yellow),? transmembrane? (orange),? and? cytoplasmic? (purple)? domains? of?Nrp-1,? along?with? the? ligand?binding?functions?and?the?relevant?targeted?amino?acid?residues?have?been?shown?color-coded.??
?
1.5 Semaphorin Family 
Semaphorins and their receptors were originally characterized as factors of the 
complex regulatory system responsible for the guidance of axons during the central nervous 
system development. Semaphorin receptors were subsequently found to be expressed by 
multiple types of cells, including endothelial cells and a variety of cancer cells (Neufeld and 
Kessler, 2008).  
The Semaphorins are a large and phylogenetically conserved family of proteins 
including both secreted and transmembrane guidance cues (Yazdani and Terman, 2006). 
Semaphorins  can  either  promote  or  inhibit  tumour  progression  through  the  regulation  of  
processes such as angiogenesis, metastasis and cell survival during cancer progression (Gaur 
et al., 2009). The family of Semaphorins contains 21 vertebrate genes and eight additional 
genes found in invertebrates. All Semaphorins are characterized by the presence of an amino-
terminal domain essential for their signalling. In vivo studies in invertebrates and vertebrates 
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have definitively shown that Semaphorins serve as pivotal repulsive cues during neural 
development (Tran et al., 2007). Among all family members, class 3 Semaphorins are the 
only secreted ones in vertebrates. Sema3A, originally called “Collapsin-1”, was the first 
vertebrate Semaphorin identified and was first characterized as a neruopilin-1 ligand. Mice in 
which the Sema3A gene has been disrupted show dramatic axon guidance deficiencies 
(Kitsukawa et al., 1997). Sema3A is basically expressed in tissues that encompass peripheral 
nerves and functions as a repellent. Transmembrane Semaphorins can also act as repellents. 
Among members of Semaphorin family, Class 3 Semaphorins and specifically Sema3A are 
competitive inhibitors of VEGF165 binding to NRPs and have been recognized to negatively 
mediate tumour growth. Key members of class 3 Semaphorins, i. e. Sema3A and Sema3D are 
synthesized as homodimers linked by disulphide binds, and this dimerization is crucial for 
their bioactivity (Klostermann et al., 1998; Koppel and Raper, 1998). Specific members of 
class 3 Semaphorin family have been supposed previously to have both tumour suppressor 
(Sema3B and 3F) (Campioni et al., 2008) and anti-angiogenic (Sema3A and 3F) effects and 
to be down-regulated with tumour progression. Indeed, the expression of Sema3B and 
Sema3F is down-regulated with increasing lesion severity in ovarian cancer (Drenberg et al., 
2009; Osada et al., 2006). Additionally, increased ratio of vascular endothelial growth factor 
to Semaphorin is a poor prognostic factor in ovarian carcinomas (Joseph et al., 2010) and also 
during lung cancer progression (Campioni et al., 2008; Tomizawa et al., 2001).  
1.5.1 Semaphorin receptors 
 
 All semaphorins in higher vertebrates contain a signature Semaphorin domain of 
nearly  500  amino  acids,  which  plays  a  crucial  role  in  mediating  the  association  of  these  
lignads with signalling receptors of plexin family. Semaphorin receptor complexes are 
composed of plexins or plexins along with neuropilins (Figure 5).  The  main  receptors  for  
semaphorins are plexin family members including nine various proteins in higher vertebrates 
(Tamagnone and Comoglio, 2000) as high affinity receptors for Semaphorins. Several 
members of Semaphorin family bind plexins directly, whereas some secreted vertebrate 
semaphorins such as Sema3A, bind to the obligate co-receptors neuropilin-1 or neuropilin-2 
to form neuropilin- plexin holoreceptor complex. The neuropilins form signalling complexes 
by associating with type A plexins. In these complexes, the neuropilins serve as the binding 
receptors and the plexins as the signal-transducing elements (Takahashi et al., 1999; 
Tamagnone et al., 1999). 
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   (Capparuccia?and?Tamagnone,?2009)?
?
Figure? 5.? Schematic? representation? of? Semaphorin? family? members? and? their? receptors?
(neuropilins?and?plexins).?A)?All?members?of?Semaphorin? family?are?recognized?by? the?presence?of? ??large?Sema?domain?and?one?PSI?domain.?Among?vertebrate?Semaphorins,?those?belonging?to?classes?4,?5,?and? ?? are? transmembrane? proteins,? while? those? in? class? ?? are? membrane? bound? through?glycophosphatidylinositol?(GPI).??Instead,?class?-3?Semaphorins?as?secreted?members?of?this?family,?have?C-terminal?basic?charged?sequences?required?for?binding?to?neuropilins.?Several?members?of?Semaphorin?family?contain? immunoglobulin-like?domains.?B)?Neuropilins?are?transmembrane?non-tyrosin?kinase?co-receptors?characterized?by?two?CUB?domains?(also?called?a1?and?a2?domains),?two?FV/FVIII?coagulation?factor-like?domains?(also?referred?to?as?the?b1?and?b2?domains)?and???meprin-like?MAM?domain?or?the???domain).?C)?Plexins?consist?of?one?Sema?domain,?two?to?three?PSI?domains?and?three?IPT?domains.??
    
1.6 Tumour Microenvironment and Metastatic Disease 
A tumour is not just a bunch of cancer cells with the ability to multiply infinitely, but 
is composed of cancer stem cells, mature cancer cells, metastatic cancer cells, stromal cells, 
endothelial cells, tumour- infiltrating macrophages and a broad variety of fibroblasts, all of 
which embedded in an extracellular matrix (ECM) and constitute what is usually called the 
“tumour microenvironment” (Joyce, 2005). The microenvironment of solid tumours is a 
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heterogeneous setting with specific features such as acidic pH, low nutrient levels, elevated 
interstitial fluid pressure (IFP) and variable levels of oxygenation characteristic of abnormal 
vascular network existing in tumours (Figure 6).  
Interestingly, the tumour microenvironment, particularly in respect with the massive 
infiltration of dysregulated immune cells can promote tumour growth, angiogenesis, and 
metastasis (Joyce, 2005). It is believed that metastatic potential of tumour cells is regulated by 
interactions between the tumour cells and their extracellular environment (ECM). In fact, 
tumour microenvironment was once believed to be a simple bystander that accompanies the 
growth and the evolution of tumour masses, primarily and essentially composed of malignant 
cells, able to proliferate restlessly. Now, the other components of a tumour are known to 
actively sustain its growth, suppressing host immune response (Kusmartsev and Gabrilovich, 
2006), secreting pro-tumourigenic growth factors (Mantovani et al., 2010), modelling the 
ECM and most prominently, fostering angiogenesis (Schmid and Varner, 2007; Shojaei et al., 
2008) and promoting metastatic spread (De Palma et al., 2007).  
Angiogenesis and metastatization are invariably linked, as blood vessels constitute the 
main route for cell dissemination. Subsequently, excessive angiogenesis leads to the 
formation of a poorly efficient vasculature and the consequent establishment of a chronic state 
of hypoxia (Wilson and Hay, 2011).  
Clinical and experimental evidence suggests that altered gene expression in response 
to the hypoxic environment plays an important role in favour of metastasis (Keith et al., 
2012), as will be discussed in Chapter 1.14.  
?  
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?(Joyce?and?Pollard,?2009)?
Figure?6.?Tumour?microenvironment.?Tumour?cells?in?primary?tumours?are?encompassed?by???complex?microenvironment?consisting?of?various?types?of?cells?including?endothelial?cells,?stromal?fibroblasts?and???broad?range?of?bone?marrow-derived?cells?(BMDCs)?including?macrophages,?TIE-2?expressing?monocytes?(TEMs),?myeloid-?derived?suppressor?cells?(MDSCs),?and?mesenchymal?stem?cells?(MSCs).?
 
1.7 Metastasis Mechanisms 
Metastasis, the spread of malignant cells from a primary tumour to distant sites, 
creates the biggest problem to cancer treatment and is the main cause of death of cancer 
patients. It occurs in a series of distinct steps represented as a “metastatic cascade” including 
Epithelial-Mesenchymal Transition (EMT), invasion, anoikis (apoptosis in response to 
inappropriate interaction between cell and extracellular matrix), angiogenesis, transport 
through vessels and outgrowth of secondary tumours. Noteworthy, alterations that disturb 
normal  control  of  anoikis,  confer  to  the  tumour  cells  the  ability  to  live  in  completely  
inappropriate extracellular matrix environment.  
According to recent findings, beside the requirement of stem cell-like properties, the 
role  of  the  tumour  stroma  and  paracrine  interactions  of  the  tumour  with  cells  in  distant  
anatomical sites, or the existence of a “premetastatic niche” has well been established.          
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In fact, the dissemination of malignant cells from the primary tumour to secondary sites was 
consistently considered to be a late-stage phenomenon. 
However, a large body of evidence demonstrated that metastasis initiation might begin 
earlier than what was previously believed. Using advanced molecular techniques, it has been 
shown that tumour cells are very often present in the blood and bone marrow of cancer 
patients before the incidence of clinical or histopathological metastasis (Alix-Panabieres et 
al., 2008). However, a novel hypothesis suggests that premalignant cells might disseminate 
during early stages of tumour progression and prime their own microenvironments or 
metastatic niches in situ (Chin, 2003). Instead, circulating cancer cells with no metastatic 
potential, might prepare distant sites to be engrafted by more invasive cell types (Bidard et al., 
2008).  Of  the  millions  of  tumour  cells  entering  the  circulation,  only  few  of  them  will  
successfully lodge and proliferate at secondary sites (Weiss, 1980, 1990). The classical view 
on the metastatic cascade, starting from a primary epithelial neoplastic lesion includes: 
Epithelial-Mesenchymal Transition (EMT) and rupture of the basement membrane barrier; 
disaggregation of tumour cells from the tumour mass; Invasion of the adjacent tissue; 
intravasation into pre-existing and newly formed blood and lymph vessels; transport through 
vessels; extravasation from vessels; establishment of disseminated cells (which can stay 
dormant for a prolonged period of time) at a secondary anatomical site; and outgrowth of 
micrometastases and macrometastases (Figure 7). In order to successfully metastasize, tumour 
cells have to overcome all the physiological barriers caused by these steps. The necessity of a 
“premetastatic niche” at the target site, before the onset of first tumour cells to the distant site 
has been proved by different studies, although the exact time of the establishment of 
“premetastatic niche” is not known. Distant tumours induce increasing levels of the pro-
inflammatory chemokines at the secondary target sites of tumour-bearing mice, which in turn 
are infiltrated by myeloid cells that crucially modify the local environment priming it for 
subsequent localization (Hiratsuka et al., 2002; Hiratsuka et al., 2006).  
Epithelial  tissues,  representing  the  origins  of  most  solid  tumours  are  separated  from  
the stroma by a basement membrane. During metastasis, epithelial tumour cells are released 
from adjacent cells and breach the basement membrane barrier. This process is suggested to 
involve specific cell alterations which are usually referred as EMT (Christofori, 2006; Thiery, 
2002). EMT, a conserved critical process for embryonic development, concerns the release of 
epithelial cells from the surrounding tissue (Radisky, 2005). During EMT, epithelial cells 
acquire characteristics resembling those of mesenchymal cells, therefore inducing cellular 
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invasion into neighbouring tissues. Cells undergoing EMT usually acquire a spindle-shaped 
morphology. The major signalling pathways and molecules inducing EMT include Receptor 
Tyrosine Kinases (RTK), the transforming growth factor ? (TGFB) superfamily, WNT, 
NOTCH, hedgehog pathway (Huber et al., 2005; Massague, 2008) and NF-kB (Huber et al., 
2004). Instead, the reverse process, Mesenchymal-Epithelial Transition (MET), seems to be 
involved in establishing secondary tumours with an epithelial appearance, reminiscent to the 
primary one (Thiery, 2002).  EMT can promote metastasis in different ways. First of all, the 
loss of cell-cell adhesion permits tumour cell invasion. Infiltration to tissues and vessels can 
be supported by a secondary property of cells that have undergone EMT, i.e. secretion of 
protein-degrading enzymes like matrix metalloproteinases (MMPs) (Jechlinger et al., 2003). 
MMPs are often overexpressed in tumours and are able to remodel the Extracellular Matrix 
(ECM) in the tumour microenvironment, eventually releasing and processing mitogenic and 
angiogenic factors sequestered by ECM. Cleavage of ECM components provides criptic sites 
that stimulate cell migration (Giannelli et al., 1997). In order to invade tissues and vessels, 
cells must reach the ability to migrate. In brief, cell migration starts with the extension of cell 
membrane projections that is driven by a continuous cycle of actin polymerization and 
depolymerization.  Invasive tumour cells can migrate either as single cells or collectively in 
the form of files, clusters or sheets.  
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???????????????????????????????????????????(Psaila?and?Lyden,?2009)?
Figure?7.?Schematic?representation?of?the?formation?of???metastatic?niche.?The?figure?illustrates?the?pre-metastatic,?micrometastatic? to?macrometastatic? transition.?a)?Secretion?of?growth? factors? including?vascular? endothelial? growth? factor-A? (VEGF-A),? placental? growth? factor? (PlGF),? transforming? growth?factor-??(TGF-?)),?inflammatory?S100?chemokines?and?serum?amyloid?A3?(SAA3)?by?the?primary?tumour?are?upregulated? in?premetastatic?areas.?This?can?eventually?result? in?clustering?of?bone?marrow-derived?haematopoietic? progenitor? cells? (HPCs).? HPCs? secrete? ??wide? range? of? pre-metastatic? factors? such? as?tumour?necrosis?factor-??(TNF-?),?matrix?metalloproteinase???(MMP9),?and?TGF-???Stimulated?fibroblasts,?secrete? fibronectin,? ??pivotal?adhesion?protein? in? the?niche,? and? lysyl? oxidase? (LOX)? expression? is? also?elevated,?with???role? in?modulating?the? local?extracellular?matrix.?b)?MTCs?engraft?the?niche?to?populate?micrometastases.? c)? Infiltration? of? endothelial? progenitor? cells? (EPCs)? to? the? early? metastatic? niche?regulates?angiogenic?switch?and?facilitates?the?progression?towards?macrometastases.??
1.8 Metastasis associated with Acute and Chronic Tumour Hypoxia 
The mechanisms by which tumour hypoxia might increase metastatic potential may 
include the increased rate of mutagenesis, genetic instability and enhanced epigenetic 
regulation of gene expression (Erler et al., 2006; Graeber et al., 1996; Krishnamachary et al., 
2003; Rofstad, 2000; Subarsky and Hill, 2003; Sullivan and Graham, 2007). The development 
of tumour hypoxia is essentially correlated with the formation of neovasculature. Vessels 
developed within tumour masses are immature, expanded, and tortuous (Vaupel, 2004). 
Because of an incomplete basement membrane, they are hyperpermeable and prone to 
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excessive branching, blind ends and neovascular shunts (Baluk et al., 2003; Kallinowski et 
al., 1989; Vaupel et al., 1989). For tumour cells, the consequence of being far from the 
vascular supply or so-called diffusion-limited hypoxia was proposed by Thomlinson and Gray 
in 1955 as the first concept of hypoxia in tumours (Thomlinson and Gray, 1955). It was 
proposed later that perfusion-limited hypoxia (also known as acute hypoxia), due to 
alterations in blood flow, might play an important role in solid tumours (Brown, 1979; 
Sutherland and Franko, 1980). Angiogenesis is a necessity of tumour growth.  
A key pro-angiogenic gene in this regard, is hypoxia-responsive VEGF (Dvorak et al., 
1999). Its expression is regulated by the hypoxia-inducible factor 1 (HIF-1) which is 
stabilized under hypoxic conditions (Semenza, 2001, 2007). HIF-1 has been considered as the 
master regulator of hypoxic response (Semenza, 2003) and drives expression of multiple 
genes that are involved in the metastatic process, although there are other transcriptional 
factors such as NF-kB, p53, AP-1, C/EBPb, Egr-1 and SP-1 that respond to an hypoxic 
environment (Hirota and Semenza, 2006; Mabjeesh and Amir, 2007; Subarsky and Hill, 2003; 
Zhou et al., 2006). HIFs are frequently up-regulated in cancer and metastasis since their 
downstream target genes can promote growth and survival (Maynard and Ohh, 2007). Nearly 
1-1.5% of the genome is transcriptionally regulated by hypoxia and many pro-metastatic 
genes are known to be regulated by HIF-1?. 
1.9 Tumour- Infiltrating Cells 
 Similar to other solid tumours, colon carcinomas are also infiltrated by various cell 
types including tumour-associated macrophages (TAMs), myeloid-derived suppressor cells 
(MDSCs), mast cells, cancer-associated fibroblasts (CAFs), monocytes, neutrophils, CD8 and 
CD4 T-cells, dendritic cells (DCs), natural killer (NK) cells, endothelial cells, endothelial 
progenitor cells (EPCs), platelets, and mesenchymal stem cells (MSCs) (Murdoch et al., 
2008). It was originally proposed that the presence of these cells is the remnant of a truncated 
immune response mounted by the host against the tumour that is ultimately unable to 
eradicate the malignancy. Now, tumour-infiltrating immune cells are considered as potent 
tumour-promoting agents with multiple genetic and pharmacological evidence, although 
specific contribution of each cell type is difficult to dissect, largely due to their overlapping 
functions. It is now extensively approved that tumour vessels are composed not only of 
sprouting vessels from pre-existing ones, but also of heterogeneous precursor cells(Furuya 
and Yonemitsu, 2008). Bone marrow-derived EPCs (endothelial progenitor cells) (Asahara et 
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al., 1997), tissue-derived EPCs (Bruno et al., 2006; Zengin et al., 2006), and some 
hematopoietic stem cells (HSCs) (Hattori et al., 2002; Lyden et al., 2001) are believed to 
evolve into tumour-associated endothelial cells (TECs). Comparison of molecular profiles 
between normal ECs and TECs including cDNA microarray analysis and proteomic mapping, 
have detected several key molecules as TECs-specific markers (Seaman et al., 2007; Shih et 
al., 2002). Some highly expressed molecules such as VEGFR2 which are not specific to TECs 
seem to contribute to the modulation of permeability, proliferation, migration, anti-apoptosis, 
matrix  remodelling,  and  many  other  aspects  of  tumour  neovascularization  (Bussolati  et  al.,  
2003; St Croix et al., 2000; Wang et al., 2002). Despite a general concept, not all of above 
mentioned cell populations differentiate into TECs. Some of these cells localize in close 
proximity of tumour vasculature as heterogeneous cells of uncertain differentiation capacities 
and contribute to tumour growth by mediating its proinflammatory microenvironment. In 
such a milieu, tumour vessels take advantage of specific signalling molecules (Furuya et al., 
2004), this cocktail of infiltrating cells preserves tumour associated inflammation, 
angiogenesis, and immunosuppression, which sequentially promotes tumour progression and 
metastasis. Two important factors for this breach are inflammation and soluble 
chemoatractants secreted by both tumour and stromal cells (Jedinak et al., 2010). The initial 
role of these stromal cells is not tumour promotion but instead, these cells contribute to some 
antitumour properties (de Visser et al., 2006). But during tumourigenesis, the dynamic 
interaction between stromal and tumour cells changes, eventually being in favour of tumour 
progression (de Visser et al., 2006) possibly involving an “education” of immune cells in loco 
by malignant cells. 
 
1.9.1 Tumour-Associated Macrophages 
Tumour-Associated Macrophages (TAMs) derive from blood monocytes that are 
recruited to the tumour by growth factors, chemokines, and angiogenic factors such as 
colony-stimulating factor 1 (CSF-1), and VEGF (Lewis and Pollard, 2006; Pollard, 2009; Sica 
et al., 2008). The presence of low interleukin (IL)-12 and high IL-10 levels in the tumour 
microenvironment induce the differentiation of monocytes into TAMs (Fricke and 
Gabrilovich, 2006). Macrophages are phenotypically plastic and, depending on the 
microenvironment stimuli, can acquire different functions and morphology in a continuum of 
phenotypic conditions whose edges are represented by either M1 (anti-tumour) or M2 (pro-
tumour) polarization states (Mantovani et al., 2007; Mantovani et al., 2004; Sica et al., 2006; 
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Van Ginderachter et al., 2008). TAMs with M2 polarization are a major tumour-infiltrating 
population of the cells (Coussens and Werb, 2002; Mantovani et al., 2008) and are an 
essential component of inflammation-associated carcinogenesis (Figure 8).  The  number  of  
M2 macrophages is preferentially raised in the poorly vascularized areas of the tumour, which 
are marked by low oxygen concentration. Under such a condition, these cells cooperate with 
cancer cells in regulating HIF-1 dependent transcription of angiogenesis inducers such as 
VEGF-A, FGF-2, and CXCL8 (Mantovani et al., 2002). High TAM density in tumours is now 
considered as a poor prognostic indicator in various tumours, including CRC (Bacman et al., 
2007; Bingle et al., 2002; Lewis and Pollard, 2006; Paik et al., 2004). TAMs promote tumour 
growth and metastasis through inducing angiogenesis and enhancing tumour cell 
migration/invasion and ECM degradation (Barbera-Guillem et al., 2002; Condeelis and 
Pollard, 2006; Leek et al., 1996; Shieh et al., 2009; Takanami et al., 1999). TAMs in the 
stroma express COX-2, and the relationship between COX-2 and colonic adenoma formation 
is well established (Adegboyega et al., 2004). Colon carcinoma cells induce TAMs to secrete 
VEGF, which promotes angiogenesis as well as metastasis (Barbera-Guillem et al., 2002; 
Pollard, 2004; Sickert et al., 2005). TAMs express many other pro-angiogenic factors, such as 
FGF2, TNF-?, IL-1?, IL-8 (CXCL8), COX-2, platelet derived growth factor-? (PDGF-?), 
hepatocyte growth factor (HGF), matrix metalloproteinase (MMP)-7, and MMP12 (Barbera-
Guillem et al., 2002; Burke et al., 2003; Leek et al., 1996; Mizukami et al., 2007; Shieh et al., 
2009; Takanami et al., 1999). Colon carcinoma cells produce CSF-1, which recruits 
macrophages to the tumour periphery where they secrete motility and angiogenic factors that 
facilitate  tumour  cell  invasion  and  metastasis  (Green  et  al.,  2009).  TAMs  contribute  to  the  
epithelial- to- mesenchymal transition (EMT), which is a primary event for cancer metastasis 
(Bataille et al., 2008; Bates et al., 2007). TGF-?, which is produced by both colon cancers 
(Paduch and Kandefer-Szerszen, 2009) and macrophages (Mantovani et al., 1992), plays a 
significant role in the process of EMT. Moreover, cancer cells can induce stromal cells 
(including macrophages) to secrete MMPs (MMP2 and MM9), cysteine cathepsins and serine 
proteases that contribute to cell invasion and intravasation by cleaving cell- adhesion 
molecules such as E-cadherin and the ECM. On the other hand, suppressive mediators 
secreted by TAMs can suppress T-cell activation and proliferation (Mantovani et al., 1992). 
Two major series of evidence connect macrophages and cancer: first, the correlation of 
chronic inflammation leading to macrophage accumulation with the initiation of cancer and 
its progression (Coussens and Werb, 2002; Mantovani et al., 2008; Robinson and Coussens, 
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2005); second, a high density of TAM is associated with poor prognosis in more than 80% of 
studies (Lin et al., 2002; Murdoch et al., 2008). Experimentally, TAM depletion by means of 
bi-phosphonate compounds (i.e. zoledronic acid) severely impairs tumour growth in different 
models of tumour growth and progression (Giraudo et al., 2004). Indeed, TAMs accumulate 
in critical regions of tumours such as hypoxic areas, and hypoxia triggers a pro-angiogenic 
plan in these cells (Murdoch et al., 2004). Macrophages are specifically noticed as 
multifunctional cells due to their diverse and opposing activities in pro- vs. anti-inflammatory, 
immunogenic vs. tolerogenic, and tissue devastating vs. tissue restoration processes. 
Macrophages from healthy or inflamed tissues are able to lyse tumour cells, to present 
tumour-associated  antigens  to  T-cells,  and  to  express  stimulatory  cytokines  for  T-  and  NK-
cells (Fidler and Schroit, 1988). The adaptability of macrophages might be taken as an 
advantage by tumour cells to acquire distinct abilities at different stages of tumour 
progression. Cancer cells can stimulate TAMs to produce matrix metalloproteinases (MMPs) 
in a paracrine manner through the secretion of different stimuli such as interleukins, growth 
factors and CD147 as an extracellular matrix metalloproteinase inducer. In addition, the 
invasiveness of the tumour cells might be supported by epidermal growth factor (EGF) 
secreted by TAMs in response to tumour-derived CSF-1, which consequently leads to the 
activation of several genes associated with the migration of tumour cells (Goswami et al., 
2005).  In fact, the invasion and chemotaxis of metastatic cancer cells as a subpopulation of 
tumour cells, relies on the co-migration of tumour-associated macrophages (Goswami et al., 
2005; Wyckoff et al., 2004; Wyckoff et al., 2007).  
 
???????(Calorini?and?Bianchini,?2010)?
Figure?8.?Origin?and?function?of?M2-polarized?macrophages.?
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1.9.2 Myeloid-Derived Suppressor Cells 
 
Myeloid-Derived Suppressor Cells (MDSCs) (Gabrilovich et al., 2007) are a 
heterogeneous population of immature myeloid cells that have suppressive effect on adaptive 
immune responses (Nagaraj and Gabrilovich, 2008). Numbers of MDSCs are increased in the 
blood of mice and patients with cancer, including CRC (Mandruzzato et al., 2009). When 
they are immature, they express endothelial markers such as CD31 and VEGFR2 and thus 
have the ability to join the tumour endothelium. It has been demonstrated that this 
heterogeneous population of immature myeloid progenitors have tumour angiogenesis-
promoting activity in both mouse tumour models (Shojaei et al., 2007a) and  human cancers 
(Almand et al., 2001; Diaz-Montero et al., 2009). These cells are composed of neutrophils, 
monocytes, and dendritic cells. In mice they are classified by the expression of Cd11b and 
Gr1 on their surface. Subsets of these cells have the potential to prevent antitumour activities 
of T cells and Natural Killer (NK) cells (Murdoch et al., 2008). Indeed, wide range of tumour-
produced stimulators, including VEGF-A, colony stimulating factors, prostaglandins, SCF, 
S100A8, S100A9, CCL2, and a large number of interleukins can recruit Cd11b+Gr1+ cells to 
the site of tumour (Gabrilovich and Nagaraj, 2009). MDSCs may differentiate into mature 
TAMs (Movahedi et al., 2008; Umemura et al., 2008). Beside their immunosuppressive 
activities, when isolated from tumour bearing mice, these cells also express higher amounts of 
pro-angiogenic factors including matrix metalloproteinases (MMPs) (Yang et al., 2004; Yang 
et al., 2008), which consequently increases the bioavailability of VEGF-A.  It has been 
demonstrated that Cd11b+Gr1+ myeloid cells also play a role in VEGF-A- independent 
angiogenesis and growth in mouse tumours (Shojaei et al., 2007a). This effect is associated to 
the secretion of the pro-angiogenic factor Bv8, which leads to the proliferation and migration 
of  endothelial  cells  in  the  absence  of  VEGF-A  (Shojaei  et  al.,  2007b).  Recent  studies  have  
also supported a role for Cd11b+Gr1+ cells in creating a pre-metastatic niche (Yan et al., 
2010), where bone marrow-derived cells prepare the microenvironment sites prior to the 
settlement of tumour cells (Psaila and Lyden, 2009). 
1.9.3 Mast Cells 
In some human tumours, infiltration of mast cells is linked with increased vascularity 
and tumour growth, invasion and poor clinical consequences (Crivellato et al., 2008; Groot 
Kormelink et al., 2009). Recent CRC studies have shown that a lower number of mast cells in 
the site of tumour are associated with hypovascularity and better survival in CRC patients 
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(Gulubova and Vlaykova, 2009). Stem cell factor (SCF) secreted by tumour cells in vivo has 
been involved in the accumulation of mast cells in the border of growing tumours (Huang et 
al., 2008). Activated mast cells secrete many pro-angiogenic and growth stimulatory factors 
such as VEGF (Crivellato et al., 2008; Grutzkau et al., 1998), FGF-2, heparin, histamine, 
TNF-?, angiopoietin-1, and proteases, thus triggering neoangiogenesis. It has been also 
shown  that  mast  cells  are  a  substantial  element  for  preneoplastic  polyp  development  
(Gounaris et al., 2007). Accordingly, the number of mast cells is significantly higher in 
primary CRCs, as well as in poorly differentiated tumours comparing with non-neoplastic 
tissues.   
 
1.9.4 Cancer Associated Fibroblasts  
 
Cancer Associated Fibroblasts (CAFs) are the major cellular component of reactive 
stroma in primary and metastatic cancer and play a key role in CRC progression (Kalluri and 
Zeisberg, 2006; Ostman and Augsten, 2009). CAFs are composed of heterogeneous 
components including tissue-resident fibroblasts, stromal smooth muscle cells and bone 
marrow (BM)-derived fibroblasts (Direkze et al., 2004). Residual tissue fibroblasts and 
fibroblast precursors stimulated by PDGF and TGF-? are also supposed to be the source of 
CAF (Peddareddigari et al., 2010).  
Cancer-associated fibroblasts are mostly specified based on the expression of ?-
smooth muscle actin (?-SMA), fibroblast-activated protein (FAP), fibroblast-specific protein-
1 (FSP1), neuron-glial antigen-2 (NG2), and PDGF ?-receptor. Studies have shown that for 
colon cancer patients with high levels of stromal FAP, the risk of having aggressive disease 
progression and developing metastases or recurrence is higher (Henry et al., 2007).  CAFs are 
a  source  of  growth  factors  and  chemokines  that  promote  tumour  growth  and  metastasis  and  
tumour cell proliferation, survival and invasion respectively (Kalluri and Zeisberg, 2006). 
Furthermore, CAF-originated chemokines recruit bone marrow-derived cells, macrophages, 
and  other  immune  cells  to  the  site  of  tumour.  The  secretion  of  VEGF,  FGF,  TGF-?),  and  
CXCL12 by CAF plays a crucial role in the promotion of tumour growth and angiogenesis 
(Dong et al., 2004; Hlatky et al., 1994).  
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1.9.5 Tie-2-Expressing Monocytes (TEMs) 
 
Tie-2, an angiopoietin receptor, mainly expressed by endothelial cells and 
hematopoietic stem cells, is also found in a class of monocytes (Venneri et al., 2007). In 
cancer patients, Tie-2 expressing monocytes (TEMs) are detected in blood and the tumour 
microenvironment, where they correspond to the main monocyte population and are distinct 
from TAMs (Venneri et al., 2007). Interestingly, TEMs have been also detected in many 
tumours including colon carcinoma (Goede et al., 2012). They contribute to tumour 
angiogenesis and growth, and likely possess a superior angiogenic capacity.  The Tie-2 
ligand, angiopoietin-2, which is mainly expressed by hypoxic tumour cells and tumour 
endothelial cells is the major factor involved in their recruitment (Lewis et al., 2007; Murdoch 
et al., 2007). 
 
1.9.6 Neutrophils 
 Infiltration of neutrophils has been detected in different stages of inflammation. In 
addition, increased number of neutrophils is evident in patients with various cancers including 
gastric and colon cancer (Roncucci et al., 2008). Remarkably, neutrophils are an essential 
element of oxidative stress-associated pathogenesis of chronic inflammatory bowel disease 
(IBD)-related RCR (Roessner et al., 2008). More recently, it has been shown that neutrophils 
are strongly involved in tumour angiogenesis.  Neutrophils are recruited into the tumour site 
from the circulation. Once inside the tumour, neutrophils can secrete factors such as 
oncostatin M, which stimulates tumour cells to secrete more vascular endothelial growth 
factor (VEGF). Tumour-associated neutrophils can modulate tumour angiogenesis by 
releasing a variety of proteases contributing to degradation and remodelling of ECM. Of these 
proteases, MMP9 has been shown to have the most effective role in mediating tumour 
angiogenesis. Proteolysis of the ECM by this MMP releases angiogenic factors such as VEGF 
and FGF-2 that are usually attached in an inactivated form to the ECM. Cytokine-activated 
neutrophils also secrete VEGF and CXCL8 by de-granulation. These potent pro-angiogenic 
factors then act directly on the nearby vasculature to promote tumour angiogenesis. Moreover, 
the interaction of neutrophils with adhesion molecules (ICAM-1) on the endothelial cell 
surface may also stimulate angiogenesis (Tazzyman et al., 2009). However, neutrophils have 
been also shown to have antitumor activities since factors released by neutrophils such as 
ROS, proteases, and cytokines such as TNF-? can kill tumour cells directly (Di Carlo et al., 
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2001a; di Carlo et al., 2001b). Thus, it was recently proposed that, depending on the tumour 
microenvironment, TANs (Tumour- associated Neutrophils) can have pro- or antitumour 
properties (Fridlender et al., 2009).  
1.9.7 Neuropilin-1 Expressing Mononuclear cells (NEMs) 
 Neuropilin-1 expressing myeloid cells were originally discovered at the site of 
angiogenesis in mouse skeletal muscles injected with AAV-VEGF-A165 (Zacchigna et al., 
2008). AAV-mediated overexpression of VEGF165 was  shown  to  recruit  a  large  number  of  
infiltrating mononuclear cells, interspersed among muscle fibres, persisted in the tissue for 
several months, and accompanied VEGF-induced angiogenesis (Zacchigna et al., 2008). 
These cells were further characterized as Nrp-1+/CD11b+/Gr1- cells involved in the process of 
blood vessel maturation and normalization and then designated as NEMs. Interestingly, a 
similar cellular infiltration was observed in adult tissues of inducible VEGF transgenic mice 
(Grunewald et al., 2006), pointing towards an invariable role of NEM recruitment in 
supporting VEGF-driven angiogenesis.  
 Remarkably, ectopic expression of Sema3A in the mouse skeletal muscle through 
AAV-mediated gene transfer elicited the attraction of NEMs, even in the absence of any 
angiogenic process (Zacchigna et al., 2008). Along with the observation that VEGF121 did not 
recruit NEMs in the same model, these data strongly support a crucial role of Nrp-1 in 
mediating cell mobilization. A detailed representation of NEM infiltration upon AAV-
mediated overexpression of either VEGF165 or Sema3A is shown in Figure 9.  
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? ? ? ? ? ? ? ? ? ? ? ? ????????(Zacchigna?et?al.,?2008)?
Figure?9.?Similar?cell?recruitment?by?VEGF165?and?Sema3A?in?vivo.?Immunohistochemistry?against??-SMA? antigen? in?mouse? skeletal?muscles? previously? injected?with? either? AAV-VEGF165? or? AAV-Sema3A?demonstrates?that?both?VEGF165?and?Sema3A,?through?binding?their?mutual?co-receptor?Nrp-1,?can?attract?NEMs?to?the?site?of?angiogenesis.?Formation?of?arteries? in?muscles?overexpressing?VEGF165? is?due?to?the?pro-angiogenic?effect?of?this?VEGF-A? isoform,?although?such?an?effect? is?not?detectable? in?mouse?skeletal?muscles?injected?with?AAV-Sema3A.??
 
 Indeed, NEMs promote vessel maturation and artery formation through the secretion of 
factors causing the recruitment of smooth muscle cells to the site of angiogenesis. 
Noteworthy, gene expression profiling showed that NEMs produce relatively low levels of 
canonical pro-angiogenic factors (Carrer et al., submitted for publication), remarkably 
distinguishing this cell type from other bone marrow-derived populations sustaining 
angiogenesis.  
 NEMs can be directly purified from the bone marrow as CD11b+/Nrp-1+/Gr1- cells and, 
when injected to the site of angiogenesis, they can actively sustain full vessel maturation 
(Zacchigna et al., 2008).  
 Prolonged  expression  of  VEGF165 in  the  skeletal  muscles  of  adult  rodents  induces  a  
strong angiogenic response, with an increase in the number of capillaries and newly formed 
arteries surrounded by ?- smooth muscle actin (?-SMA) positive cells.  
 Consistently, VEGF121 does not disply any arteriogenic capacity, as is not able to elicit 
the formation of ?-SMA+ vessels at physiological doses. Importantly, VEGF121 promote EC 
proliferation at an extent comparable to VEGF165, as expected by its exquisite angiogenic 
potential. Accordingly, the Molecular Medicine Laboratory proposed a working model in 
which vessel maturation is elicited specifically by VEGF165 in an indirect way, which implies 
the recruitment of NEMs as accessory cells, peculiarly able to attract mural cells thus 
allowing vessel coverage and stabilization (Figure 10). Indeed, NEMs contribute to arterial 
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formation through a paracrine effect resulting in the activation and proliferation of local 
smooth muscle cells present in the tissue. 
  
 
 
 
 
 
 
 
 
 
 
? ? ? ? ? ? ? ? ? ? ? ? ?
?
? ? ? ? ? ? ? ? ? ? ? ? ????????(Zacchigna?et?al.,?2008)?
?
Figure?10.?Role?of?NEMs?in?vessel?stabilization.?The?recruitment?of?NEMs?by?both?VEGF165?and?Sema3A?as?ligands?of?Nrp-1?plays???major?role?in?vessel?maturation.???wide?range?of?growth?factors?secreted?by?this?population?attracts?smooth?muscle?cells?and?pericytes?to?the?site?of?ongoing?angiogenesis,?which? in?turn?contribute?to?vessel?coverage?and?stabilization.??
  
 NEMs  do  not  infiltrate  mouse  experimental  tumours,  consistent  with  their  ability  to  
favour vessel stabilization, and do not have an equivalent human counterpart so far, as Gr1 is 
a marker present only in mice. Hence, their relevance in the context of human malignancy is 
still unexplored. 
 Importantly, Sema3A has been shown to exert anti-tumour activity in a variety of 
mouse models, including xenotransplantation (Kigel et al., 2008), orthotopic implantation 
(Carrer, unpublished) and spontaneous carcinogenesis (Maione et al., 2009). Whether this 
effect could be, at least in part, due to recruitment of NEM has been extensively investigated 
at the Molecular Medicine Laboratory. Indeed, administration of purified NEMs significantly 
inhibited tumour growth (Carrer, unpublished), an event concomitant with the normalization 
of tumour vasculature and improved oxygen perfusion. Previous data strongly point towards 
NEMs as a strong normalizing agent in the context of tumour angiogenesis. NEM-induced 
improvement in tumour perfusion contributes to the inhibition of tumour progression through 
amelioration of tumour-associated hypoxia.  ?
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1.9.8 Lymphocytes and Dendritic Cells 
 
 It  has  been  shown  that  tumours  without  early  metastatic  invasion  signs  contain  
increased number of recruited immune cells and elevated amount of markers of T-cell 
migration,  activation,  and  differentiation  (Pages  et  al.,  2005).  In  fact,  the  type,  density,  and  
location of T-cells in some colon cancer tissue samples, has been shown to be a better 
predictor  of  patient  survival  than  histopathological  results  used  to  stage  CRC (Galon  et  al.,  
2006; Morris et al., 2008). Moreover, the role of B-cells in human CRCs is not well 
described, but B-cells may inhibit antitumor T-cell responses by antigen-nonspecific 
mechanisms (Shah et al., 2005).  Dendritic cells (DCs), both myeloid and plasmacytoid DCs 
are able to induce primary and secondary T- and B- cell responses, thanks to their antigen 
presenting capacity. Tumour-derived factors such as VEGF, ?-defensin, CXCL12, HGF, 
CXCL8, and PGE2 recruit  immature  DCs  (iDCs)  in  the  site  of  tumour  but  prevent  their  
maturation (Gabrilovich et al., 1998), resulting in a cellular infiltrate composed of few mature 
DCs but abundant iDCs. These iDCs promote tumour angiogenesis by releasing pro-
angiogenic cytokines and functioning as a source of endothelial progenitors (Curiel et al., 
2004). On the other hand, mature DCs may induce tumor-specific cytotoxic T lymphocyte 
(CTL) activity against colon tumor growth in vitro and in vivo (Wu et al., 2009). 
 
1.9.9 Platelets 
 
 Platelets are nucleus-less cells basically involved in hemostasis. On the other hand, they 
have  been  also  observed  to  play  a  crucial  role  in  tissue  repair  and  the  conservation  of  
endothelial function (Mazzucco et al., 2010). Moreover, evidence suggests that increased 
number of platelets can contribute to tumour progression, possibly through enhanced 
production of growth factors normally required for tissue repair. Other evidence indicates a 
role of platelets in tumour metastasis and angiogenesis (Karpatkin, 2003; Nash et al., 2002). 
In cancer patients, platelets are activated by thrombin, ADP, or by direct contact with 
molecules on the surface of tumour cell membranes. Platelet activation outcome is the 
generation of thromboxane A2 and the release of the storage contents from both alpha 
granules  and  dense  granules  that  contain  pro-angiogenic  factors  such  as  VEGF,  PDGF,  and  
CXCL12 (Stellos et al., 2009). Platelets are also involved in colon cancer metastasis by being 
accumulated on embolic tumour cells, thus protecting them from elimination by the immune 
system (Kopp et al., 2009). 
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1.9.10 Mesenchymal Stem Cells 
 Colon tumours, as many other types of solid malignancies, contain various multipotent 
cells, including Mesenchymal Stem Cells (MSCs), Endothelial Progenitor Cells (EPCs), and 
pericyte progenitor cells beside cancer stem cells (Ricci-Vitiani et al., 2009). Remarkably 
important among these are the MSCs, which are multipotent nonhemopoietic cells that reside 
in the bone marrow and can differentiate into various types of mesenchymal cells.  They are 
characterized by the expression of a large number of adhesion molecules and stromal cell 
markers including CD73, CD105, CD44, CD29, and CD90 and the absence of hematopoietic 
markers (CD34, CD45, and CD14) or endothelial markers (CD34, CD31, and vWF). MSCs 
give  rise  to  a  large  number  of  cytokines  and  growth  factors  such  as  PDGF,  FGF,  and  
CXCL12. They also express growth factor receptors and ECM proteins.  
 In bone marrow, MSCs and MSC-derived stromal fibroblasts sustain hematopoiesis. 
However, in primary tumours, they are present in large numbers and contribute to the 
formation of tumour- associated stroma. They also promote tumour growth and metastasis 
(Karnoub et al., 2007) partly by their immunosuppressive effects and pro-angiogenic 
properties. MSCs can also be differentiated into endothelial and pericyte-like cells that 
support tumour growth. In addition, MSCs have been supposed to play a role in   promoting 
the cancer stem cells’ survival (Ning et al., 2008). 
1.10 Lymphatic vasculature and its role in metastatic spread in cancer 
? Lymphatic vasculature is an important gate of metastasis in various cancer types. 
Spread of tumour cells to lymph nodes has been usually recognized as an early event in 
metastatic disease relevant to the staging of the cancer (Tuttle, 2004). In addition, lymphatic 
vasculature and lymph nodes are fundamental for immune function.  
 The lymphatic capillaries are composed of an irregular basement membrane and a single 
layer of endothelial cells deprived of tight junctions. These characteristics are crucial for the 
function of lymphatic capillaries, since they simplify the ingression of lymphocytes, proteins 
and fluids into the vessels (Oliver and Detmar, 2002; Skobe and Dana, 2009). Moreover, 
pericytes or smooth muscle cells are missing in lymphatic capillaries, although the larger 
lymphatics are also composed of smooth muscle cells involved in pushing lymph through the 
vessels (Saharinen et al., 2004). In fact, preventing regional lymph node metastasis in some 
animal models has been associated with lower metastasis rate at distant sites, proclaiming the 
existence of a pathway for organ metastasis through lymph nodes (Alitalo et al., 2004; 
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Krishnan et al., 2003; Stacker et al., 2002).   
1.11 The cancer vasculature 
 As previously mentioned, tumour vessels branch in an irregular serpentine manner, with 
the tendency to connect to each other haphazardly (Baluk et al., 2005; Jain, 1988, 2005; 
Mazzone et al., 2009; Nagy et al., 2010). In addition, the tumour vasculature is highly 
heterogeneous and displays a wide range of vessel subtypes including capillaries, ‘mother’ 
vessels, which are characterized as large, leaky vessels encompassed by pericyte-depleted thin 
walls,  and  also  glomeruloid  vessel  protuberances  and  vascular  malformations(Nagy  et  al.,  
2010; Pettersson et al., 2000). Some vessels seem oversized whereas smaller vessels display 
some sort of immaturity (Fukumura et al., 2010; Jain and Stylianopoulos, 2010).  
 In  fact,  comparing  to  the  healthy  vasculature,  as  a  result  of  a  persistent,  uncontrolled  
production of angiogenic factors, which tips the balance in favour of excessively active vessel 
growth, tumour vessels are structurally and functionally abnormal (Figure 11). Tumour 
perfusion  is  chaotic  in  such  a  way  that  blood  may  flow  easily  in  certain  areas  while  being  
stagnant in others (Fukumura et al., 2010; Jain, 1988). Irregularities in the flow patterns in 
tumour vasculature, subsequently causes an interruption in the process of constant delivery of 
nutrients as well as chemotherapeutics (Jain, 2005; Jain and Stylianopoulos, 2010). Indeed, in 
some areas, ECs with indiscriminate shape are piled upon each other and block blood flow by 
extending several outgrowths, while in other locations, ECs fade away or die behind 
intracellular gaps. These abnormalities are detectable in a wide variety of tumour types but 
not every tumour demonstrates the same degree of vessel abnormality (Rocha and Adams, 
2009).    
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          (Carmeliet?and?Jain,?2011)?
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Figure? 11.?Tumour? vessels? are? abnormal? in? their? function? and? structure.? a)? In? a? healthy? normal?tissue,???well-structured?vasculature?is?formed,?which?is?encompassed?by?normal?pericyte?coverage?of?the?vessel?wall.?
b)?Instead,? in?tumours,?the?vascular?network?displays?structural?and?functional?anomalies,?mainly?at?the?level?of?vessel?wall,?resulting?in?poor?perfusion?and?severe?hypoxia? in?some?certain?regions.?BM,?EC,?and?IFP?stand?for?basement?membrane,?endothelial?cell,?and?interstitial?fluid?pressure?respectively.??
?
?
?? Moreover, the vessel wall of tumour is also abnormal. Since their wall is compressed by 
tumour or stromal cells, diameters are asymmetrical. Tumour-associated endothelial cells 
have a unique activated phenotype compared to normal quiescent endothelial cells. Whereas 
normal vessels are lined with a tightly connected and impenetrable monolayer of endothelial 
cells aligned in the direction of blood flow, simulated tumour endothelial cells can easily 
detach from the basement membrane and pile upon each other (Baluk et al., 2005; Mazzone et 
al., 2009; Ozawa et al., 2005). Consequently, some tumour endothelial cells might die or 
dismount, resulting in the formation of some gateways to facilitate the access of escaped 
cancer cells to the blood flow through so-called ‘mosaic vessels’ (Jain, 1988) lined with both 
endothelial and tumour cells. In fact, tumour endothelial cells generate sprouts and form 
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abluminal extensions, with their tip cells pervading the tissue. On the other hand, tumour 
endothelial cells go through endothelial-to-mesenchymal transition leaving their default 
position.  
 Tumour blood vessels are exposed to a distinct combination of stimuli in their regional 
environment and are controlled by abnormal signalling pathways (Figure 12). In other words, 
cancer cells by their oncogenic transformation features or response to hypoxic conditions, 
release a collection of stimuli that trigger the transformation of their local environment. These 
factors stimulate the remodelling of the extracellular matrix to facilitate tumour growth and 
progression. Tumour cells as well as stimulated endothelial cells secrete a variety of soluble 
factors involved in the mobilization and homing of bone marrow-derived myeloid cells and 
their subsequent differentiation into tumour-associated macrophages and neutrophils. In such 
an environment, receptors on the surface of endothelial cells bind factors that trigger 
intracellular signalling pathways and thus promote a cascade of phenotypic changes leading to 
migration, invasion, survival and proliferation of these endothelial cells.  
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           ???????????????(Weis?and?Cheresh,?2011)?
Figure?12.?Regulators?of? endothelial? activation? and? tumour? angiogenic? response.?FN,? fibronectin;?Col,?collagen;?VN,?vitronectin;?LN,?laminin;?TUMs,?tumstatin;?END,?endostatin;?CANS,?canstatin.??
?   ?
1.12 Abnormal vessel maturation in pathological angiogenesis 
 During physiological vessel maturation, alterations in blood flow, metabolic 
requirements, and growth factor secretion results in vessel remodelling. Some vessels follow 
the process of maturation through the secretion of extracellular matrix (ECM) by endothelial 
and encompassing stromal cells ensued by recruitment of pericytes and vascular smooth 
muscle  cells  to  the  growing  vessels  (Hellstrom et  al.,  2001).  Pericytes  and  vascular  smooth  
muscle cells on their surfaces express Angiopoietin-1 (Ang-1) that subsequently binds to Tie-
2 receptors on the surface of endothelial cells. This close interaction between endothelial cells 
and mural cells (vascular smooth muscle cells and pericytes) results in the activation of TGF-
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?, and consequent stimulation of basement membrane production (Holderfield and Hughes, 
2008). The basement membrane is a specialized ECM construction made of sheet-like 
matrices that are closely attached to the cells and one of its major roles is to provide structural 
support for the nascent vessels (Gustafsson and Fassler, 2000). Whereas under normal 
physiological circumstances, interaction between Ang-1and its receptor stabilizes the integrity 
of vessel junctions, secretion of high levels of Ang-2 by sprouting endothelial cells, compete 
for binding to Tie-2, leading to destabilization of pre-existing vessels (Adams and Alitalo, 
2007; Eklund and Olsen, 2006).   
 In a healthy tissue, mural pericytes with their stellate-like appearance and their unique 
ability to encompass the endothelium play a crucial role in sustaining a mechanical backbone 
for delicate endothelial channels. Pericytes are basically located around EC junctions and by 
forming umbrella-like constructions cover the gaps between ECs. Pericytes and their adjacent 
ECs are implanted within the same basement membrane and thus establish tight connections 
between each other. Additionally, among the most important functions of the basememt 
membrane, it is noteworthy to mention its crucial role in selective transport of components 
and cells and storage of angiogenic factors (Diaz-Flores et al., 2009; Eble and Niland, 2009). 
The  basement  membrane  of  the  tumour  vessel  is  deprived  of  tight  connections  with  
endothelial cells, is made of various irrelevant layers and has an abnormal thickness. As a 
result of constant tumour vessel remodelling, it is highly probable that under such a condition, 
endothelial vessels are no longer encompassed by a basement membrane.  Pericytes as shields 
of endothelial cells secrete low levels of endothelial survival factors, such as VEGF and are 
eventually responsible for blood flow irregularities. Indeed, pericyte coverage of tumour 
vasculature is much less than normal tissues and is highly variable between tumours and even 
in the same tumour. In addition, since mural cells prevent breaching of the vessel wall by the 
intravasation of cancer cells, it seems reasonable that tumour cells spread through pericyte-
deficient vessels is highly facilitated.  
 In a large number of human diseases and tumours, abnormal vessels are considered as 
one of the main characteristics of the malignancy. Indeed, an abnormal vasculature is now 
considered a hallmark of solid tumours (Jain, 2002; Jain et al., 2002). In other words, from the 
physiological point of view, the basic differences between the normal and tumour tissues 
originate from the tumour vasculature. Vascular network in tumours is composed of two 
categories of vessels: the pre-existing vessels in normal tissues into which the tumour has 
invaded; and tumour microvessels born through the process of neovascularization as a 
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consequence of increased expression of pro-angiogenic factors. In this respect, the two kinds 
of vessels form different structural and physiological abnormalities (Brown and Giaccia, 
1998). These abnormalities in concert with the compression of blood vessels by cancer cells 
(Padera et al., 2004) eventually impair blood supply to the tumour. As a consequence, blood 
flow is often sluggish or delayed and highly irregular. In addition, the vessels are exceedingly 
permeable, if compared to those in healthy tissues. The oxygen diffusion distance in solid 
tumours can be nearly 100-150 µm (Dewhirst et al., 1994). Accordingly, tumour cells away 
from the effective oxygen diffusion distance may be exposed to low oxygen tensions, thus 
affected by hypoxia. Similarly, in such a hypoxic area, anticancer chemotherapeutics could 
not efficiently reach tumour masses at toxic concentrations (Durand, 1994).  
 The clinical and pathological relevance of vessel abnormalization is further underscored 
by the fact that through up-regulation of angiogenic factors by cancer and stromal cells, which 
in turn further supports vessel disorganization, hypoxia stimulates non-productive 
angiogenesis in a constant self-reinforcing circuit. Indeed, abnormal tumour vasculature might 
disrupt the function of immune cells in tumours. As a consequence, abnormal tumour 
vasculature can cause tumour resistance to radiation therapy and a wide range of 
chemotherapeutics.  
 In this respect, traditional anti-angiogenic-based therapies focus on inhibiting the 
formation  of  new  blood  vessels  and/  or  to  demolish  existing  ones  to  starve  the  tumour 
(Folkman, 1971). Originally foreseen as a promising therapeutic approach to treat a broad 
variety of solid tumours, anti-angiogenic compounds have met a significant disappointment 
when translated to the clinical practice. Much of this setback is possibly due the aberrant 
organization of tumour vasculature and the intrinsic tumourigenic potential of tumour-
associated hypoxia. In this respect, normalizing tumour vasculature improves tumour vessel 
perfusion and oxygenation, which consequently leads to reduced metastasis rate and more 
efficient chemo and immune therapy approaches (Hamzah et al., 2008; Mazzone et al., 2009; 
Stockmann et al., 2008). In fact, preclinical evidence has demonstrated that normalization of 
vascular abnormalities might be considered as a promising therapeutic paradigm for cancer 
and other vascular diseases affecting more than half a billion people worldwide.  
1.13 Anti-angiogenic therapies 
 As mentioned before, VEGF is an essential mediator of tumour-associated 
angiogenesis. Concomitantly, in 1971, anti-angiogenic therapy was proposed as a tactic to 
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treat solid tumours. Fourteen years after the cloning of VEGF-A in 1989, the first VEGF- 
targeted agent, the anti-VEGF monoclonal antibody bevacizumab (Avastin, Genentech) as a 
VEGF-neutralizing antibody showed clinical benefits in metastatic colorectal cancer patients 
when combined with chemotherapy (Figure 13). Nevertheless, in certain cancers, the clinical 
use of VEGF blockers such as VEGF receptor tyrosine kinase inhibitors which block the 
signaling of pathways such as VEGF, are only effective when exploited as monotherapy, 
whereas they might be toxic in combination with chemotherapy (Jain et al., 2006; Jain et al., 
2009). 
  VEGF-targeted therapy might limit the permeability of the vessels induced by VEGF, 
constrict dilated ones and as a result improve blood flow.  
 To date, two main obstacles currently impede non-surgical treatment of solid tumours. 
First of all, tumour physiological barriers hinder the delivery of therapeutics at effective 
concentration to all cancer cells (Jain, 1998). Moreover, acquired drug resistance originating 
from genetic and epigenetic mechanisms decreases the effectiveness of available drugs 
(Browder et al., 2000; Klement et al., 2000). Anti-angiogenic therapy has the ability to 
overcome these problems or at least decrease their impact. This specific sort of therapy targets 
the tumour vessel network by affecting endothelial cells. In fact, a majority of cancer cells for 
their growth and survival depend on a small number of residual or circulating endothelial 
cells. Blocking VEGF or its receptor VEGFR2 results in the apoptosis of endothelial cells and 
as a consequence, a reduction in vessel diameter, density and permeability (Kadambi et al., 
2001; Tsuzuki et al., 2000; Yuan et al., 1996). 
 However, anti-angiogenic therapy seems more challenging than anticipated. Many 
patients with metastatic cancer are refractory or develop resistance to VEGF inhibitors. 
Additionally, whether anti-angiogenic therapy can cause tumour cells to become more 
malignant has yet to be further elucidated (Ebos et al., 2009; Paez-Ribes et al., 2009). Indeed, 
various anti-angiogenic techniques seem to be more effective in preclinical than clinical 
settings.  
 As mentioned before, a fraction of cancer patients are refractory to VEGF-inhibitor 
therapy (Bergers and Hanahan, 2008). The extent of resistance differs from one cancer to 
another, varies between micro and macrometastatic state, and also depends on the type of 
VEGF blocker exploited. Patients can be either intrinsically refractory or develop resistance 
during the process of treatment. In this regard, several mechanisms contributing to changes in 
tumour cells, endothelial cells or other stromal cells have been speculated to explain the 
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occurrence of resistance in both cases (Bergers and Hanahan, 2008; Carmeliet, 2005; Jain et 
al., 2006; Jain et al., 2009). At a more advanced stage, due to the production of other pro-
angiogenic factors, tumour angiogenesis might become VEGF independent and consequently 
respond poorly to anti-VEGF treatment.  
 By normalizing tumour vasculature (before its elimination), low-dose anti-angiogenic 
therapy improves the delivery of drugs and oxygen to the tumour. Whereas anti-angiogenic 
therapy alone can prevent tumour growth, a large body of evidence has demonstrated that this 
sort of therapy along with radiation and chemotherapy results in long term cures in mice 
(Browder et al., 2000; Klement et al., 2000). Since both radiation therapy and chemotherapy 
strictly rely on sufficient blood flow to the tumour to transport oxygen and drugs respectively, 
normalization of the tumour vessels through anti-angiogenic therapy can be considered as a 
putative explanation why standard anti-angiogenic therapies give rise to a better outcome 
when combined with radio/chemotherapy. In recent years, some challenging questions have 
been raised in the field of anti-angiogenic cancer therapy: in order to achieve tumour 
shrinkage and starve primary tumours from oxygen, should tumour vessels disruption be the 
focus  of  therapy,  or  instead,  should  they  be  normalized  to  improve  responses  to  routine  
anticancer therapies? Based on the fact that each individual approach has its own advantages, 
one  novel  possibility  is  to  combine  these  two  strategies  to  complement  current  anti-
angiogenic therapeutic policies. Moreover, it has been previously demonstrated that in a 
mouse model of pancreatic islet tumourigenesis, inhibition of major VEGF-A receptors 
(VEGFR1 and VEGFR2) using monoclonal antibodies could initially block angiogenesis and 
tumour growth (Casanovas et al., 2005). However, due to the resistance to anti-VEGF 
receptor therapy, successive tumour progression accompanied by revascularization of the 
tumour was observed. This resistance was then characterized by the compensatory 
upregulation of VEGF-A, FGF-1, FGF-2, FGF-7, and FGF-8, ephrin-A1, and Ang-2.  
 Despite significant investments and several small molecule inhibitors of angiogenesis 
currently  subjected  to  clinical  trials  (Ivy  et  al.,  2009),  bevacizumab,  as  an  anti-VEGF  anti-
angiogenic antibody is now used as a first line treatment only along with conventional  
chemotherapy regimens for treatment of metastatic colorectal cancer. Many retrospective 
studies now suggest that antineoplastic effects of this drug might be due to normalization of 
abnormal tumour vasculature, reduced intratumoral hydrostatic pressure along with increased 
vessel permeability, which allows more effective drug delivery to the tumour(Ferrara et al., 
2004; Jain, 2001; Willett et al., 2004). Interestingly, since radiotherapy and certain 
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chemotherapy approaches strictly rely on the formation of reactive oxidative species to hit 
tumour cells, tumour hypoxia could reduce the efficacy of conventional anticancer treatments 
(Moeller et al., 2007).  
 On the other hand, induction of hypoxia through vessel relapse after VEGF blockade 
can trigger a more invasive and metastatic pattern, while in other cases, tumour stem cells by 
acquiring extra mutations can become hypoxia-tolerant. Although HIF-1 can be considered as 
an important therapeutic target, there are other multiple pathways responsive to hypoxia. 
Moreover, in vivo studies hypothesize that alternative angiogenic pathways might be activated 
when a single factor such as HIF-1 is inhibited.  Another important influence of hypoxia is to 
induce radio/chemotherapy resistance in solid tumours. In fact, under hypoxic conditions, by 
activating HIF-1 mediated pathway, tumour cells have demonstrated an increased 
chemoresistance (Comerford et al., 2002) and radioresistance (Moeller and Dewhirst, 2006). 
On the other hand, it has been also demonstrated that chronic hypoxia can increase 
radiosensitivity due to a decreased homologous recombination capacity and DNA double-
strand break repair in hypoxic tumour cells (Chan et al., 2008). In this regard, overexpression 
of the ATP-binding cassette (ABC) transporters family members in cancer tissues have been 
shown  to  pump  anticancer  drugs  out  of  the  cancer  cells  and  thus  to  be  responsible  for  
chemoresistance to a wide range of these reagents. Indeed, HIF-1? has been described as an 
ABC transporter genes transcription regulator in tumour cells (Gottesman et al., 2002; Park et 
al., 2006). On the other side of the coin, hypoxic tumour cells secrete some amounts of 
VEGF, which is subsequently associated with progression of angiogenesis, increase in 
paracrine/autocrine growth factor secretion, tumour growth, and increase in the rate of 
metastasis.   It  has  been  also  shown  that  VEGF165 –transfected xenografts show highly 
vascularized tumours with an accelerated growth rate and enhanced chemoresistance (Zhang 
et al., 2006).  
 Altogether, these observations highlight the diversity and complexity of the tumour 
angiogenic response. As a consequence, better understanding of the full range of either HIF-
dependent or HIF-independent angiogenic mechanisms seems a basic necessity to be able to 
design optimal combinations of anti-angiogenic agents. In other words, knowing how anti-
angiogenic therapeutics act in vivo and what types of drugs can be combined to result in better 
outcome in certain patients are crucial steps in achieving successful anti-angiogenic strategies. 
Beside this, tumour vessel normalization can play a critical role in increasing the efficacy of 
anticancer therapies by ameliorating the oxygenation of the tumour and subsequent 
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modulation of the secretion of various cytokines and growth factors to the site of malignancy. 
Accumulative  body of  evidence  shows that  tumour  vessels  are  normalized  after  anti-VEGF 
therapy, resulting in fewer but more efficient vessels with proper pericyte coverage, which 
supports better drug delivery to the tissue (Dickson et al., 2007; Inai et al., 2004; Mancuso et 
al., 2006). In other words, anti-angiogenic therapies affecting both endothelial proliferation 
and vessel stabilization have been shown to be more effective on tumour progression than 
only targeting the VEGF signalling (Bergers et al., 2003). Despite the fact that prolonged anti-
VEGF therapy can eventually demolish most of the vessels, tumours can shift towards 
alternative pathways of angiogenesis and become resistant to VEGF blockade. Consequently, 
an interesting area of research at present can be to answer the question whether and how the 
normalization of vessels by anti-VEGF therapy can be sustained to achieve a prolonged 
benefit.   
 Therefore, anti-angiogenic therapy requires especial consideration of signalling 
components and receptor crosstalks among a wide range of cell types, considering the fact 
that tumour cells can persist growing in VEGF-independent manner (Shojaei et al., 2007b) by 
utilizing alternative pro-angiogenic signallings. These complicated interactions play a crucial 
role in angiogenic remodeling and can be involved in de novo or  acquired  resistance.  To  
achieve a successful anti-angiogenic strategy, it is of high importance to consider these 
signaling effects in the context of various cell types involved in the continually altering 
tumour microenvironemt. These therapeutic responses can be extended to the suppression of 
endothelial progenitor cells infiltration and damages of cancer stem cells (CSCs) niche 
located in the proximity of tumour vasculature. It is also expected that anti-angiogenic 
therapies provide better prognosis by indirect disruption of cancer stem cells (Gilbertson and 
Rich, 2007).   
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                    ???(De?Bock?et?al.,?2011)?
Figure?13.?Anti-VEGF?therapy?acts?as???normalizer?for?tumour?vessels.?Anti-VEGF?treatment?prunes?the?immature?blood?vessels?and?thus?stabilizes?the?persisting?vessels?by?enhancing?their?pericyte?coverage?through? the? induction? of? Ang-1? and? PDGFR?? signalling.? Accordingly,? neutralization? of? VEGF? reduces?tumour? vessel? permeability? and? ameliorates? tumour? perfusion? and? oxygenation,? which? consequently?results?in???better?penetration?and?higher?efficacy?of?chemoterapeutics.???
1.14 Role of hypoxia in physiological and pathological angiogenesis 
 Hypoxia is among the most important physiological stimuli to induce angiogenesis and, 
consistently, a substantial component of tumour progression. Hypoxia is generally defined as 
a reduction in the ambient oxygen concentration. During the process of hypoxia-induced 
tumour progression, cancer cells can establish an increased potential for invasive growth as 
well as regional and distant metastasis (Vaupel and Mayer, 2007; Vaupel et al., 2004). Indeed, 
hypoxia is established in the most interior regions of solid tumours due to abnormal 
vasculature and irregular intratumour blood flow (Yasuda, 2008). 
 In ischaemic conditions, tissue perfusion is reduced in such a way that oxygen 
availability is no longer sufficient to fulfil tissue metabolic requirements. In fact, hypoxia is a 
well-known regulator of many aspects of cell biology (Simon and Keith, 2008). Cells respond 
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to such environmental stress by activating several regulatory pathways. Expectedly, 
expression of almost all crucial angiogenic factors, including vascular endothelial growth 
factor (VEGF) is induced by hypoxia, as improving blood supply is the primary response to 
inefficient oxygen delivery (Figure14). Most of the effects of the hypoxia are associated with 
the transcriptional activity of hypoxia inducible factor-1 (HIF-1). HIF-1 mediates a 
transcriptional response in a cell type specific manner involving an organized expression of 
growth factors by diverse cell types within the hypoxic tissue. On the other hand, beside 
hypoxia, other pathways can also increase the expression of HIF-1? in tumours under 
normoxic conditions (so-called hypoxic mimicry conditions). Production of vascular 
endothelial growth factor (VEGF) in tumour cells is regulated by the activated HIF-1? 
regulated system. Increased levels of VEGF subsequently induce the accumulation of HIF-1? 
and promote tumour metastasis through angiogenesis. In fact, intratumoural hypoxia, as a 
frequent observation in metastatic cancers results in the activation of Hypoxia-inducible 
factors. HIFs are involved in different steps of metastatization, including metastatic niche 
formation through increasing the expression of various enzymes implicated in remodelling 
collagen at the metastatic site and recruiting bone marrow-derived cells (BMDCs) to the 
metastatic niche. In the case of breast cancer patients, overexpression of HIF-1? is associated 
with an increased risk of metastasis and mortality and may benefit from HIF-inhibitor therapy 
(Wong et al., 2012).   
 Additionally, it has been found that loss of HIF-1? in endothelial cells decreases nitric 
oxide (NO) synthesis, delays tumour cell migration through endothelial layers, and reduces 
tumour cell metastasis whereas loss of HIF-2? has opposite effects (Branco-Price et al., 
2012). These contradictory effects stem from differential regulation of NO homeostasis that 
subsequently modulates VEGF expression in an NO-dependent response loop, but still 
highlight  the  pivotal  role  of  HIF-mediated  transcriptional  program  for  the  regulation  of  
tumour angiogenesis. 
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               (Latham?et?al.,?2010)????
Figure?14.?Factors?regulating?the?blood?concentration?of?VEGF-A.?VEGF-A?is?produced?and?secreted?by?inflammatory? cells? of? the? tumour? microenvironment? under? hypoxic? stress.? This? results? in? the?establishment?of? ??VEGF-A?concentration?gradient? in? the?blood.?Excess?VEGF-A?can?be?metabolized?and?eliminated? as? nitrogenous? waste.? However,? VEGF-A? is? also? removed? from? the? bloodstream? through?binding? to?endothelial?receptors?(VEGFR1?and?2)?and?co-receptors?(HSPGs,?neuropilins)?or?sequestered?within?the?bloodstream?by?the?soluble?form?of?VEGFR1,?sFlt-1.??
?
??
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2. AIM OF THE STUDY 
?
The  target  of  this  research  was  primarily  to  unravel  the  roles  of  the  two  major  
expressed  isoforms  of  VEGF-A  (termed  as  VEGF-A165 and VEGF-A121) in human tumour 
angiogenesis, development and prognosis. Previous findings of the Molecular Medicine 
laboratory have demonstrated that these two VEGF-A splicing isoforms have divergent 
effects in mouse models of both physiological and pathological angiogenesis. In particular, 
despite a comparable capacity to activate the local endothelium, only VEGF-A165 successfully 
elicited full maturation of newly-formed blood vessels. Indeed, VEGF-A165 overexpression 
resulted in improved vessel architecture and function whereas VEGF-A121 primarily 
stimulated mere capillary sprouting. This difference is particularly relevant during tumour 
angiogenesis, as in such a context abnormal vascularization is favourable and leads to 
accelerated tumour growth and increased invasiveness. Thus, using tissue specimens of 
colorectal carcinoma (CRC) as a pathological model of angiogenesis, the initial idea was to 
assess whether human malignancies display a preferential expression of one of these isoform 
and to correlate it with the outcome of CRC in a predefined and statistically representative set 
of the patients. The expression levels of the two isoforms in the tumour mass were compared 
with levels in a matched, non-malignant tissue sample. The VEGF-A165 /VEGF-A121 ratio was 
then correlated with the clinical outcome and with patient prognosis.  
Moreover, biological diversity of VEGF isoforms intriguingly is correlated with their 
differential ability to recruit a peculiar myeloid sub-population of bone marrow-derived 
myeloid cells (subsequently characterized as NEMs), which in fact exert a potent paracrine 
activity on pericytes and smooth muscle cells, by promoting the coverage and consequent 
stabilization of neoformed blood vessels. When mice skeletal muscles were pre-conditioned 
with VEGF165 as one of the recruiters of NEMs, challenging the same location with malignant 
cells resulted in two chronological predominant outcomes: first, the significant infiltration of 
Nrp-1+/CD11b+ BM-derived cells to the site of tumour angiogenesis, and second, the 
indicative prevention of tumour growth through its vascular network normalization. In other 
words, when recruited to the tumour microenvironment, an outstanding role of this unique 
Nrp-1+/CD11b+ myeloid cells is to contribute to the maturation of tumour vasculature. 
Recruitment or ectopic administration of NEMs in mouse tumours results in decreased 
tumour growth, possibly as a final outcome of normalization of tumour vasculature. We thus 
also  explored  the  possibility  that  human  tumours  expressing  abundant  levels  of  VEGF165 
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indeed exhibited improved clinical outcome and NEM infiltration. In this respect, another 
novel aspect was to evaluate the existence of NEMs at the sites of human tumours expressing 
abundant levels of VEGF165.  
Subsequently, we investigated the expression of Semaphorin-3A (Sema3A) in human cancers, 
as it has been described as a potent NEM recruiter, similarly to VEGF165, but differing for the 
absence of any angiogenic activity. 
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3. MATERIALS AND METHODS 
3.1 Patients recruitment  
Consecutive patients scheduled to undergo surgical resection of tumour mass at the 
Department of Surgery of the Azienda Ospedaliero-Universitaria ‘Ospedali Riuniti di Trieste’ 
of Trieste, Italy were recruited for this study, with no specific criteria for exclusion. All 
patients were enrolled according to protocols approved by the Ethical Committee of the 
Azienda Ospedali- ero-Universitaria ‘Ospedali Riuniti di Trieste’, after written informed 
consent was obtained. The tumour mass was entirely removed and samples were frozen at      
–80°C. Apparently healthy mucosa samples were harvested for each patient, at least 10 cm 
away from the tumour mass.  
For each patient, tumour paraffin inclusions were sectioned and analysed by an 
independent group of pathologists. Tumour diagnosis and staging were determined according 
to commonly accepted criteria, including TNM and Dukes’ classification, UICC staging, 
grade, vascular and lymphatic extra-parietal invasion, as routinely determined in all patients 
with colorectal cancer.  
3.2 RNA Extraction Procedure 
? ? ? Total  RNA  from  the  CRC  biopsy  specimens  was  extracted  using  TRIzol  reagent  
(Invitrogen) according to manufacturer’s instructions. RNA extraction was then followed by 
DNase  treatment  using  DNaseI  (Roche)  to  remove  DNA  contamination.  The  isolated  RNA  
was then subjected to the synthesis of first-strand cDNA using hexameric random primers 
(Invitrogen). Reverse transcription was carried out using Moloney murine leukaemia virus 
reverse transcriptase (MLV RT). The cDNA was then used as a template for PCR 
amplification to detect the expression level of VEGF165 and VEGF121.  
3.3 Relative quantification of VEGF splicing isoforms 
? ? ? VEGF-A165 and VEGF-A121 relative  abundance  was  quantified  through  semi-
quantitative PCR. A set of primers matching exon 3 and exon 8 (thus able to amplify all 
VEGF isoforms) was employed. Primers sequences: CAG CAC AAC AAA TGT GAA TGC 
(Forward  primer)  and  GAG  GCT  CCT  TCC  TCC  TGC  (Reverse  primer). Thermal cycling 
conditions were 94°C for 5 min, followed by 40 cycles of 94°C for 15 sec, 65°C for 15 sec, 
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and 72°C for 15 sec. The obtained amplicons were then separated using polyacrylamide gel 
electrophoresis and visualized by ethidium-bromide staining. Band intensity was measured 
using VersaDoc imaging system (BioRad) as volume intensity/area (mm2). Values were 
normalized against background signal. When either mucosa or tumour sample could not be 
visualized, corresponding patient was discarded from the study. 
3.4 Quantification of total VEGF-A and Sema3A mRNA 
? ? ? To?assess?the?abundance?of?VEGF-A?and?Sema3A?transcripts? in?human?tumours?and?matching?mucosae,?cDNA?was?amplified?by?Real-Time?PCR?(BioRad),?using???human?specific? TaqMan? assay? (Applied? Biosystems).? Following? assays? were? used:?Hs00173626_m1? (for? VEGF-A)? and?Hs00173810_m1? (for? Sema3A).? The? reaction?was?performed?according?to?manufacturer’s? instructions.?GAPDH?transcript?abundance?was?similarly?assessed?using? ??human?GAPDH-specific?TaqMan?assay? (Applied?Biosystems)?and?utilized?as???house-keeping?gene?to?normalize?expression?values.?
3.5 Histology 
   Samples for histological evaluation were formalin-fixed and paraffin-embedded for 
routine post-surgical analysis at the Department of Anatomo-Pathology at Cattinara Hospital, 
in Trieste. A small subset of samples was snap-frozen in liquid nitrogen, as indicated in the 
text. 
   For immunohistochemistry, 5-µm sections were hydrated and different antigen 
retrieval  methodologies  were  performed  as  listed  in  Table  2  in  the  chapter  of  Results.  The  
following  anti-Nrp-1  antibodies  were  tried  at  different  dilutions  and  different  incubation  
conditions (clone EPR3113, ABCAM; clone EPR3113, EPITOMICS; Immunogen NS0-
derived rh Neuropilin-1, R&D). After treatment, slides were rinsed in PBS and signals were 
developed using 3, 3’-diaminobenzidine as a substrate for peroxidase chromogenic reaction 
[DAB Plus Substrate System (Thermo Scientific)]. 
   For vessel immunofluorescence, 5-µm paraffin-embedded sections were stained with 
the following antibodies were used: anti-vWF (Polyclonal Rabbit Anti-Human Von 
Willebrand Factor, DakoCytomation), Cy3-conjugated anti-?-SMA (clone 1A4, Sigma), 
diluted 1:100 in PBS + 2% BSA. Antigen retrieval was performed using citrate buffer. Nuclei 
were counterstained with DAPI. Images were acquired using a Leica MLB upright 
fluorescence microscope (Leica Microsystems, Wetzler, Germany) equipped with a Coolsnap 
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CF  CCD  camera  (Roper  Scientific,  Evry,  France).  Signals  were  quantified  by  the  use  of  
ImageJ software. 
   For NEM detection, 4-µm frozen sections were air dried and post-fixed with Zinc 
solution (BD Pharmingen). The following antibodies were diluted 1:100 in PBS supplemented 
with 2% BSA: anti-Nrp-1 (clone EPR3113, ABCAM) and anti-CD11b (clone M1/70, BD 
Pharmingen). Nuclei were counterstained with DAPI. Images were acquired using a Leica 
MLB upright fluorescence microscope (Leica Microsystems, Wetzler, Germany) equipped 
with a Coolsnap CF CCD camera (Roper Scientific, Evry, France). 
3.6 Cell culture and treatments 
 HUVEC (human endothelial cell line) were purchased from Clonetics (San Diego, CA) 
and cultured in their own medium, provided by the manufacturer. 4T1 (mouse breast cancer 
cell line), T241 (mouse fibrosarcoma cell line) and B16.F10 (mouse melanoma cell line) were 
all purchased from ATCC (Rockville, MD) and cultured in RPMI medium 1640 (4T1) or 
Dulbecco’s modified Eagle’s medium (T241 and B16.F10), both supplemented with 10% 
Foetal Bovine Serum. 
 5x105 cells were seeded onto 60-mm tissue culture dish and, upon reaching 70-80% 
confluency, were submitted to environmental stress. 
 Hypoxic conditioning was achieved through incubation in a dedicated hypoxic chamber 
for the indicated periods of time. An anoxic chamber and an O2-controlled hypoxic incubator 
(Ruskinn INVIVO2 200) were employed. 
3.7 HIF-1? quantification 
 RNA was extracted from cell cultures using Trizol Reagent (Invitrogen) according to 
manufacturer instructions. cDNA was obtained through retro-transcription as described above 
and utilized as template for Real-Time PCR. HIF-1a expression was quantified using SYBR 
Green  technology  employing  the  following  primer  set:  GAA  TGC  TCA  GAG  GAA  GCG  
AAA  (Forward  primer)  and  ACA  GTC  ACC  TGG  TTG  CTG  CA  (Reverse  primer).  Data  
were normalized against ?-actin gene expression. 
?  
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3.8. Statistical analysis 
 One-way ANOVA and Benferroni/Dunn’s post-hoc test was used to compare multiple 
groups.  Pair-wise comparison between groups was performed using the Student’s t test. 
P<0.05 was considered statistically significant. Graphs report ± SEM in each column. 
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4. RESULTS 
4.1 Sample collection from colorectal cancer patients  
? In  this  study,  colorectal  carcinoma  (CRC)  was  considered  as  a  human  model  of  
pathological angiogenesis. Biopsies of tumour and adjacent healthy mucosa were harvested 
from 78 colorectal cancer patients scheduled to undergo surgical resection of the primary 
tumour mass. This cohort of patients was homogeneous for sex and tumour location, and 
included mostly patients with advanced malignancy (Stage III and IV). For a detailed 
description of the cohort of enrolled patients, see Table 1 (Appendix).  
 Collected  samples  were  then  stored  in  TRIzol  at  -80°C  until  RNA  extraction  was  
performed. Notably, among these analysed specimens, for a small set of CRC patients (n=19), 
an additional biopsy corresponding to the peripheral zone of the primary tumour was 
collected. To avoid any contamination at the moment of surgical resection, mucosa was 
harvested at least 10 cm far from the core lesion, reasonably allowing to consider it as a 
normal, “healthy” mucosa (Figure 1).  
 Next,  by  employing  the  competitive  PCR  method,  all  known  VEGF-A  isoforms  were  
amplified, using primers designed to amplify all splicing variants (annealing at the level of 
two exons, 4 and 8, always included in the final transcript, as shown in Figure 2). By 
measuring the intensity of the corresponding bands (volume intensity/mm2) on ethidium 
bromide-stained polyacrylamide gel, the relative abundance of the two mainly expressed 
splicing isoforms of VEGF-A, i.e. VEGF-A165 and  VEGF-A121,  was  then  assessed.  In  
practice, the intensity of the bands corresponding to these two isoforms was separately 
measured, subtracted from the background intensity, and then used for further calculations. In 
this way, the ratio between VEGF-A165 and VEGF-A121 was calculated in both mucosa and 
tumour of 78 CRC patients. Such a balance is hereafter indicated as the VEGF-A165/VEGF-
A121 ratio. Importantly, this technique permits to specifically investigate the relative 
abundance of different VEGF-A isoforms in the same sample. Absolute quantification of 
mRNA  levels  was  not  considered  in  these  settings,  since  the  objective  of  this  study  was  to  
specifically correlate the ratio between the two isoforms, and not their absolute levels, with a 
series of clinical and histological parameters. In this respect, the VEGF-A165/VEGF-A121 ratio 
might represent a very informative parameter to understand if the expression of one isoform 
or another is favourable in certain clinical settings. Indeed, as extensively discussed in the 
“Introduction”, cell transformation and microenvironmental stimuli can alter isoform usage to 
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Fig.?2.?Primer?design.???primer?pair?was?designed?on?exon???(Forward?primer)?and?exon???(Reverse? primer)? in? order? to? amplify? all? splicing? isoforms? of? VEGF-A?with? pro-angiogenic?effects.?Localization? in?respect?to?VEGF?gene?structure? is?schematically?shown?in?the?Figure.?The?length?of?the?resulting?PCR?amplicons?has?been?reported?in?the?adjacent?table.?
sustain tumour progression. 
?
?
 
 
 
 
 
 
 
 
Fig.?1.? ?Sample?collection.?In???set?of?colorectal?cancer?patients,?biopsy?specimens?from?the?core?of?the?lesion?and?adjacent?healthy?mucosa?were?collected?at?the?moment?of?surgical?resection?and?processed?for?analyses.? In? ?? small? category?of? the?CRC?patients,?additional?biopsies? from? the?periphery?of? the? lesions?were?harvested? to?assess? the?difference?between? the?expression? level?of?VEGF165?and?VEGF121? isoforms?corresponding?to?the?location?of?the?malignancy.??
?
?
?
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4.2 Evaluation of primer efficiency 
? Competitive PCR is a well-established and widely used technique for semi-quantitative 
analysis (Zentilin and Giacca, 2007). It allows precise and reproducible measurements, but its 
accuracy is strongly affected by primers specificity: in this respect, it is crucial that primers 
amplify both competitors with the same efficiency (Zentilin and Giacca, 2007). In the specific 
case of VEGF isoform amplification, the two primers perfectly match to all isoforms, and thus 
these act as internal competitors for the reaction. 
 The  efficacy  of  PCR  primers  was  assessed  by  amplifying  PCR  serial  dilutions  of  a  
mixture containing equimolar concentrations of two plasmids carrying either VEGF165 or 
VEGF-A121 cDNA (pAAV- VEGF165 and pAAV- VEGF-A121, respectively – previously 
utilized in the Molecular Medicine Laboratory). Gel analysis confirmed that our primer set 
was indeed able to amplify either isoform with the same efficiency, as clearly shown in Figure 
3, where both bands are equally intense for any of the tested reactions.  
 
 
 
 
Fig.? 3.? Primers? efficiency? assessment.? Electrophoresis? on? polyacrylamide? gel? demonstrates? the?equivalent?efficacy?of? the?designed?primers? to?amplify? two?different? isoforms?of?VEGF-A?by?PCR.? ?Serial?dilutions?of? ??mixture,?containing?equimolar?concentrations?of? two?plasmids? carrying?either?VEGF165?or?VEGF121?cDNA?were?used?as?templates?for???series?of?PCR?reactions.?The?relevant?PCR?products?were?then?loaded?in?adjacent?wells?(1-5).?Bands?corresponding?to?VEGF165?and?VEGF121?display?equal?intensity?in?all?tested?PCR?conditions.?As???negative?control,?dH2??was?used?as???template?for?this?reaction?(line?6).?100?bp?molecular?weight?was?loaded?in?the?first?well.?Quantifications?are?shown?in?the?graph?on?the?right.?
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4.3 Robustness of the band intensity quantification 
 In order to evaluate the accuracy and reproducibility of technique exploited for 
quantification  of  VEGF-A  isoforms,  in  a  randomly  selected  subset  of  samples,  VEGF-
A165/VEGF-A121 ratio was repetitively measured 3 to 4 times per each and the mean of these 
values was calculated. As shown in the Figure 4, the vast majority of the measurements 
displayed only minimal variations, almost entirely encompassed in a 25% confidence interval 
(C.I.).  
 In keeping with these data, the above described methodology was considered as a robust 
and reliable procedure for VEGF-A isoform quantification and further applied to the whole 
sample set to assess the VEGF-A165/VEGF-A121 ratio. 
 
 
 
 
?
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Fig.?4.?Robustness?of?VEGF?splicing?analysis.?Twelve?randomly?selected?tumour?samples?were?subjected?to? repeated? quantification? of? VEGF165/VEGF121? ratio.? After? RNA? extraction? and? consequent? PCR?amplification? of? the? two? isoforms,? VEGF165/VEGF121? ratio? was? measured,? and? this? methodology? was?repeated?up?to?three?to?four?times?for?each?individual?sample?and?loaded?on?different?polyacrylamide?gels.?The?mean?value?of?all? the?measurements? for?each? sample?was? calculated.?Variance?of?VEGF165/VEGF121?ratio? from?mean?value?was?evaluated? for?each?measurement?and?plotted?as? squared?dots? in? the?graph?above.??
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4.4 VEGF121 is the most abundant VEGF-A isoform in both healthy mucosa and tumour 
samples 
As the first novel observation, and in disagreement with published data (Ferrara, 2010), it was 
unveiled that VEGF121 was the most abundant isoform expressed in CRC specimens. In fact, 
after  PCR  amplification  and  gel-electrophoresis,  the  VEGF121-related amplicon was 
constantly found to be more abundant than that corresponding to VEGF165 (Figure 5).   
Graphical representation of PCR band quantification is shown in Figure 6, where average 
intensity of either VEGF121- or VEGF165-related bands are plotted. The graph clearly shows 
that VEGF121 is  significantly  more  expressed  than  VEGF165, both in mucosa (mean= 33037 
vs. 14945 Int/ mm2) and tumour (mean= 35628 vs. 17904 Int/ mm2).  
?
?
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4.5 Lack of significant difference between VEGF-A splicing isoforms in CRC and paired 
mucosa samples 
 The VEGF165/VEGF121 ratio in tumour and in mucosa was assessed for 78 patients. The 
mean of these values for mucosal and tumour samples were 0.442 ± 0.207 and 0.483 ± 0.226 
respectively (no statistically difference was observed) (Figure 7). Further, the ratio between 
VEGF165/VEGF121 in  the  tumour  and  VEGF165/VEGF121 in its paired mucosa 
({VEGF165/VEGF121 Tumour}/{VEGF165/VEGF121 Mucosa}) was evaluated for each patient 
(hereinafter  referred  to  as  T/M  distribution),  and  plotted  in  Figure 8 (each dot represents a 
single patient).  
Fig.? 5.? Representative? image? of? PCR-
amplified? VEGF? isoforms.? Band? intensity?(coloured? rectangles)? was? evaluated? and?normalized? for? background? value.? VEGF121?(lower? bands)? is? invariably? the? most?abundant? isoform? expressed? in? colorectal?cancer?specimens.?
Fig.? 6.? Isoform? quantification.? Quantification? of?VEGF121? and? VEGF165? expression? in? both? healthy?mucosae? and? tumour? mass? specimens.? Values? are?expressed? as? arbitrary? units? of? band? intensity.? Bars?show?mean???s.e.m.?
?
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VEGF-A isoforms balance did not appear obviously regulated in CRC patients. Indeed, 
the VEGF165/VEGF121 ratio average was unaffected upon malignant transformation 
({VEGF165/VEGF121 Tumour}/{VEGF165/VEGF121 Mucosa}?1). As a consequence, T/M 
distribution was clearly centred on 1 (Figure 8). However, the aforementioned patient 
distribution was broad, reflecting the high heterogeneity of VEGF isoforms proportion in 
CRC patients.  This was more evident in Figure 9, where changes in VEGF165/VEGF121 ratio 
were shown for each of the analysed patient. The vast majority of the samples showed a 
marked variation in VEGF-A isoforms content between normal and malignant tissue 
specimens,  thus  clearly  suggesting  that  carcinogenesis  has  a  strong  impact  on  VEGF-A  
splicing, even though this phenomenon does not follow an obvious trend. 
?
?
?
?
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 Band intensity quantification in either normal mucosa or tumour mass specimens 
revealed that there was no significant difference in the total expression level of 
VEGF165/VEGF121 between tumour and its paired mucosa in a large set of colorectal cancer 
patients. In other words, despite a massive inter-personal variability in isoform ratio, no 
obvious trend in the modulation of VEGF-A splicing was observed. However, considering the 
mucosa and tumour sample of each patient, a large variability could be observed within the 
ratio of VEGF165/VEGF121 in mucosa vs. its matched tumour sample; this ratio has been either 
elevated in some tumour samples comparing their paired mucosae or dramatically decreased 
in the rest of the specimens.  
Fig.?7.?Isoform?quantification?in?mucosae?and?tumours.?VEGF-??splicing?balance? was? expressed? as? the? ratio? between? VEGF165? and? VEGF121??VEGF165/VEGF121?ratio?in?mucosae?and?tumours?was?calculated?for?the?entire?sample?set.?Bars?show?mean???s.e.m.?No?statistical?difference?was?observed?between?mucosae?and?tumours.?
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Fig.? 8.? Patient? distribution? according? to? T/M? ratio.? Using? band? quantification? approach,?VEGF165/VEGF121?ratio?was?separately?measured? in?healthy?mucosa?and? tumour?sample?of?each?patient.?The?obtained?value?from?tumour?was?then?divided?to?the?corresponding?value? in?the?mucosa.?As?shown?here,? the? final? ratio?values,? (VEGF165/VEGF121? in? tumour?divided? to?VEGF165/VEGF121? in?mucosa?of?each?patient)? was? plotted? in? ?? scatter? graph.? ? Each? dot? corresponds? to? an? analysed? patient.? Values? were?distributed?around?value?1,?indicating?the?fact?that?in?the?majority?of?the?patients,?VEGF165/VEGF121?ratio?had?been?remained?unchanged?between?mucosae?and?their?tumour?counterparts.??????
?
?
?
?
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Fig.?9.?Variability?in?VEGF165/VEGF121?ratio?between?mucosa?and?tumour?mass?of?each?patient.?Large?heterogeneity?was?observed? in?the?data?set.?Black? lines?denote? individual?patients?whose?ratio?has?been?found? substantially? unchanged? between? normal? and?malignant? tissue.? Conversely,? red? and? blue? lines?denote?decreased?and?increased?ratios,?respectively.??
Ratio?(T/M)?
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4.6 The correlation between VEGF165/VEGF121 ratio and tumour grading in colorectal 
cancer patients 
 Primary  aim of  this  project  was  to  correlate  the  VEGF isoforms balance  with  clinical  
tumour outcome in the cohort of the CRC patients, seeking for a parallelism between the 
observed molecular and clinical heterogeneity, although clinical data was not available for 
some of the patients for whom experimental analysis was performed (see Table 1 in Appendix 
for complete clinical evaluations of the recruited patients).  
 Tumour grading and other major clinical parameters had been routinely assessed at the 
moment of surgical resection by independent pathologists. Based on above described 
quantifications, the mean VEGF165/VEGF121 ratio  was  calculated  in  two  groups  of  CRC  
patients with low grading and high grading tumours (G=0&1 and G=2&3, respectively). In 
both cases, VEGF165/VEGF121 ratio in tumour mass was higher than in mucosa, even if this 
trend did not reach statistical significance. Comparing the average VEGF165/VEGF121 ratio in 
tumours from the two subgroups of patients, it was noticeably lower in high grading tumours, 
although this difference did not reach statistical significance (Figure 10). 
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Fig.?10.?VEGF?splicing?and?tumour?grading.?VEGF165/VEGF121?ratio?in?low?grading?and?high?grading?CRC?patients.?VEGF165/VEGF121?ratio?was?calculated?in?mucosae?and?tumours?of?patients?showing?differentiated?tumours?(G=0?and?G=1,?assessed?by? independent?pathologists).?The?same?was?assessed? in?patients?with?grading?level?of???and???(G=2&3).?Coloured?bars?show?mean???s.e.m.?Interestingly,?in?patients?with?higher?grading?level,?this?ratio?had?been?decreased?in?both?mucosae?and?tumour?specimens?compared?to?G=0&1.?
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Fig.?12.?VEGF? splicing? and? tumour? staging.?T/M?ratio?in?patients?accrued?according?to?cancer?staging?at?the?moment?of?surgery.???
Fig.?11.?VEGF?splicing?and?lymph?node?infiltration.?T/M?ratio?(VEGF165/VEGF121? in?tumour?vs.?mucosa)?in?patients?showing?lymph?node?infiltration?(N+??is?lower?if? compared? to?patients?who?were?diagnosed?with?no?lymph?node?infiltration?(N-).?Bars?show?mean???s.e.m.?
? Lymph node infiltration (N) is another important hallmark of poor clinical outcome. 
Interestingly, T/M ratio was lower in patients with infiltrated lymph nodes (N?1), as shown in 
Figure 11, even if this decrease did not reach statistical significance. 
Both observations, even though statistically not relevant, might imply that higher VEGF165 (or 
lower VEGF121) expression to some extent hurdles tumour progression towards poorly 
differentiated stages.  
 It is worth mentioning the fact that this correlation is not maintained for other clinical 
parameters, most notably tumour stage (S), as shown in Figure 12. 
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4.7  Patients  with  higher  VEGF165/VEGF121 expression ratio in their tumour mass 
demonstrate better outcome 
 
 Exploiting AAV-mediated gene transfer, it was demonstrated that VEGF165 or VEGF121 
conditioning clearly exerts distinct effects on tumour growth in mouse animal models, as 
detailed in the Introduction section. In particular, VEGF165 acts in a peculiar and rather 
surprisingly tumour suppressive manner, hampering tumour growth through the recruitment 
of NEMs and eventual vessel normalization (Carrer et al., submitted).  Although in the CRC 
samples we did not detect any obvious correlation between higher VEGF165 expression and 
better prognosis, possibly due to the vast dispersal of data, we nevertheless selected a 
restricted  subset  of  CRC  patients  (n=6),  in  whom  the  VEGF165/VEGF121 ratio was strongly 
higher in the tumour mass, compared to its paired normal mucosa. In particular, these patients 
were selected because their T/M ratio exceeded a 90% C.I., shown as green dots in Figure 13. 
 Strikingly, this small subset of patients (hereinafter referred to as VEGF165hi) displayed 
a significantly reduced lymph node infiltration, compared to the rest of the patients in the 
selected cohort (Figure 14). In contrast, the patients who conversely expressed higher levels 
of VEGF121 (T/M ratio exceeding 90% C.I., violet dots in Figure 13, hereafter VEGF121hi) did 
not exhibit any difference compared to the whole residual dataset (hereafter VEGF165int, black 
dots in Figure 13). This is in agreement with experimental evidence, supporting a differential 
impact of VEGF isoforms on tumour progression.  
 
 
 
 
Fig.?14.? ?Lymph?node? infiltration? in?VEGF165hi?
patients.? Number? of? positive? lymph? nodes? in?VEGF165int? (black? dots),? VEGF121hi? (purple? dots)?and?VEGF165hi? (green?dots)?patients? is? shown? in?this? graph.? VEGF165hi? patients? show? no? lymph?node?infiltration.?
?
Fig.? 13.? Patient? distribution? according? to? VEGF?
splicing.? Patients? were? divided? into? ?? groups.?Individuals?showing???T/M?ratio?that?exceeds???90%?CI?were?denoted?as?VEGF165hi? (green?dots)?and?VEGF121hi?(purple? dots),? for? highest? and? lowest? ratios,?respectively.? Remaining? patients? were? denoted? as?VEGF165int?(black?dots).?Lines?denote?median?±?90%?CI.?
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4.8 VEGF165hi patients exhibited a more mature tumour vasculature 
 Preliminary evidence in experimental animal models clearly demonstrates that 
VEGF165-driven tumour inhibition is correlated with an improvement in the tumour 
vasculature maturation, as mentioned before. In order to assess whether the clinical 
amelioration observed in VEGF165hi patients was linked to improved tumour vascularization, 
immunofluorescence (IF) analysis was performed on paraffin-embedded tumour specimens, 
routinely  harvested  at  the  time  of  surgical  resection  for  standard  histopathological  analysis.        
The morphology of the vascular network in patients with high expression level of VEGF165 
was compared with the cohort of the patients with high expression level of VEGF121.    
Double immunostaining against von Willebrand factor (vWF) and alpha-smooth muscle actin 
??-SMA) was employed; the former as a marker of endothelial cells and the latter as a marker 
of mural cells (specifically smooth muscle cells). As it is appreciated in the following images 
(Figure 15), vessels of VEGF165hi tumours appeared more normalized and mature in respect to 
those of VEGF121hi patients. In this regard, ?-SMA was considered as an indicator of vessel 
maturation, numerically expressed as a ratio between ?-SMA and vWF fluorescence (both 
measured as pixels over a fixed threshold) displaying higher value for VEGF165hi sample 
(Figure 16). Moreover, the intensity of vWF was also measured in tumour vessels of all 
subsets of the patients showing higher intensity in the sample belonging to VEGF121hi patient 
(Figure 17). Importantly, the number of vessels was not affected by isoform selection (data 
not shown), and CD31 positivity assessed independently by routine histopathological analysis 
did not show any variation (data not shown). This again points toward a specific role of 
VEGF165 in promoting full vessel maturation, despite the fact that it retains the strong 
angiogenic capacity common to all VEGF-A isoforms. 
 Unfortunately,  given the paucity of VEGF165hi samples it was not possible to establish 
any significant correlation with effectiveness of neo-adjuvant therapy, a clear and definitive 
indicator of vessel normalization (Carmeliet and Jain, 2011). 
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Fig.?15.?Tumour?vessel?analysis.?Double?immunostaining?against?vWF?and??-SMA?in?paraffin-embedded?tumour? sections? harvested? from? VEGF121hi? (panels? above)? and? VEGF165hi? (panels? below).? Anti-vWF?antibody? labels? endothelial? cells? (EC)? and? is? shown? in? green,?whereas? antibody? against? ?-SMA? labels?mural?cells?and?is?shown?in?red.?As?displayed?in?right-hand?panels?above,?in?VEGF121hi?patients,?vessels?are?scantly?covered?with?smooth?muscle?cells?indicating?poorly?mature?vascular?network.?In?left-hand?panels,?this? observation? has? been? shown? with? lower? magnification.? In? contrast,? in? the? panels? below,?immunofluorescence? experiments? for? VEGF165hi? patients? are? shown.?Most? of? the? vessels? show? ?? high?coverage? of? smooth?muscle? cells? and?pericytes? ??-SMA+??both? at? lower? (left-sided?panels)? and?higher?(right-sided?panels)?magnifications.?Split?anti-vWF?(green)?and?anti-?-SMA?(red)?signals?were?also?shown?besides?merged?images.?Nuclei?are?counterstained?in?blue?with?DAPI.?
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Fig.?16.?Quantification?of? IF?analysis.?Quantitative?evaluation?of? IF?analyses? in? VEGF165int?? VEGF121hi? and? VEGF165hi? patients? according? to?the? ratio? of? ?-SMA/vWF.?Bars? show?mean? ?? s.e.m.?Asterisk? denotes?statistical? significance? (p<0.05).? VEGF165hi? patients? clearly? show?enhanced?vessel?maturation.?
Fig.?17.?Quantification?of?vascular?area.??vWF?intensity?in?VEGF165int??VEGF121hi? and? VEGF165hi? tumours.? Bars? show?mean? ?? s.e.m.? Asterisk?denotes?statistical?significance?(p<0.05).?
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4.9  The  effect  of  higher  VEGF165/VEGF121 ratio on the occurrence of metastasis in 
colorectal cancer patients  
 There is an ample consensus that hypoxia consequent to impaired vessel functionality 
results in reduced tumour cell growth and subsequent reduced tumour mass, however whether 
normalization is beneficial in impeding tumour metastasis or, on the contrary, favours the 
metastatic process is still unclear (De Bock et al., 2011). Hence, in keeping with the 
observation that VEGF165 elicits vessel stabilization, the correlation between the presence of 
distant metastasis and the ratio of the expression of VEGF165/VEGF121 was investigated. We 
found that, in metastasis-free patients (M=0), the VEGF165/VEGF121 ratio  was  significantly  
lower when compared to metastasis-bearing patients (M=1), as shown in Figure 18 A. These 
data appear consistent with recently published data supporting the concept that vascular 
normalization induced by anti-angiogenic therapies might elicit tumour cell spreading and 
metastasis in some settings (Ebos et al., 2009; Paez-Ribes et al., 2009). In this respect, it is 
worth mentioning the role of hypoxia in the up-regulation of VEGF165 and in hypoxia-induced 
tumour metastasis, which will be discussed in subsequent sections.  
  Further exploring the issue, it was evident that in patients with no sign of metastasis, 
the mean value of VEGF165/VEGF121 expression in both mucosa and tumour did not show any 
significant difference (see Figure 18A). However, in M=1 patients this value was decreased in 
mucosae when compared to the tumour samples, and, notably, equally reduced if compared 
with mucosae from M=0 patients (Figure 18B). This was completely unexpected, as mucosa 
samples should represent “normal” tissue specimens, unaffected by either tumour presence or 
its outcome. It might be conceptualized that the down-regulation of VEGF165 or, instead, the 
up-regulation of VEGF121 in the mucosa sample of metastatic patients sets some sort of 
predisposition in CRC patients to develop very aggressive tumours. Since there are no clues to 
better understand the abundance of which one of these isoforms is more affected during the 
process of metastasis, this topic needs to be better elucidated.  
?
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Fig.?18.?VEGF?splicing?and?metastasis?A)?T/M? ratio? in?metastasis?positive? (M=1)?and?negative? (M=0)?patients.?Ratio?was?elevated? in?M=1?patients.?B)?VEGF165/VEGF121?ratio?in?mucosae?and?tumours?of?M=0?and?M=1?patients.?Bars?show?mean???s.e.m.?
4.10 Detection of NEMs in tissue sections of CRC patients 
 In our laboratory, using a mouse model of tumour xenotransplantation, we unveiled a 
dissimilar  and  somewhat  opposite  effect  of  VEGF165 and VEGF121 on tumour growth, by 
which the former decreased tumour growth while the latter increased it, compared to 
untreated animals. This difference was ascribed to the diverse ability of these two isoforms to 
recruit NEMs to the site of angiogenesis (Carrer et al., submitted). As previously mentioned in 
the “Introduction”, Neuropilin-1 Expressing bone marrow-derived Myeloid cells (NEMs) 
have been recently considered as a crucial population of BM-originated cells recruited to the 
site of physiological and pathological angiogenesis. NEMs have been recognized as 
CD11b+Nrp1+Gr1- cells in diverse animal models (Carrer et al., unpublished;  Maione et al., 
unpublished), but their detection and characterization in humans have been hampered by 
several  obvious  difficulties,  above  all,  the  lack  of  Gr-1  homologs  in  humans  and  the  
impossibility to overexpress VEGF165 or Sema3A in human tissues.  
 In respect of the above issue, partial but critical focus of this project was to detect the 
presence of NEMs in human tumours, taking advantage of the fact that a handful of tumours 
did express above-the-average levels of VEGF165 (see Figure 13),  a well-known attractor of 
NEMs (Zacchigna et al., 2008). For this purpose, 5 µM-thick sections of paraffin-embedded 
CRC tissues from VEGF165hi patients were analysed. Immunohistochemistry (IH) experiments 
were performed using an anti-Nrp-1 antibody. Unfortunately, despite using various antigen 
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retrieval procedures in order to unmask Nrp-1 antigen and trying different protocols, results of 
IH experiments were not satisfying. Some representative images are shown in Figure 19 and a 
complete list of unmasking solutions used for antigen retrieval is detailed in Table 2. 
 The feasibility of such an approach was reasonably hindered by original sample 
processing. As these samples were initially collected for routine histopathological analysis, 
they underwent strong, automatized fixation and processing, not compatible with poorly 
sensitive immunostaining. In this respect, it is important to note that Nrp-1 is a poor 
immunogen, and good staining antibodies have not been developed yet.   
?
?
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Fig.?19.?IHC?analysis.?Immunohistochemistry?experiments?on?paraffin-embedded?tissue?sections?of?CRC?patients:?anti-Nrp-1? immunostaining?was? tentatively?performed?on?paraffin-embedded? tumour?sections.?Representative?images?unveiling?negative?results?are?shown.?
?
?
 
 
Table?2.?Reagents?used?for?Nrp-1?antigen?retrieval?on?CRC?paraffin-embedded?tissue?sections.???
To overcome these problems, we took advantage of the commonly recognized fact that 
commercially available Nrp-1 antibodies work almost exclusively on freshly-frozen tissues. 
For  this  reason,  an  additional  set  of  CRC  patients  (n=19)  were  recruited  for  the  above  
described VEGF isoforms analysis. For each of these patients, a frozen biopsy was harvested 
at the time of surgical resection, and kept at -80°C for further immunofluorescence (IF) 
analysis. Five-?M cryosections were randomly obtained from some of these samples and then 
subjected to IF staining to check whether the freezing procedure of the specimens in the 
hospital  was  reliable  enough  to  maintain  the  morphological  features  of  the  tissue.  IF  
experiments were performed using anti-CD11b and anti-Nrp-1 antibodies, in order to unveil 
IHC? Paraffin-embedded?tissue?sections? L.A.B?solution?IHC? Paraffin-embedded?tissue?sections? Citrate?buffer?PH6?IHC? Paraffin-embedded?tissue?sections? EDTA?PH8? ?Tris-HCl?PH8?IHC? Paraffin-embedded?tissue?sections? Trypsin?working?solution?PH11?IHC? Paraffin-embedded?tissue?sections? Proteinase?K?IHC? Paraffin-embedded?tissue?sections? Proteinase???and?Trypsin?
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eventual double positive cells, which might be considered as putative human NEMs.  
Unfortunately, quantification of VEGF isoforms revealed that none of these recently collected 
samples showed strong expression level of VEGF165. Instead, all of them showed a balanced 
VEGF165/VEGF121 ratio  between tumour  and  mucosa  (as  shown in  Figure  20,  where  all  the  
dots fall within a 90% C.I. calculated on the entire sample set). In keeping with this 
observation, and despite the fact that a significant number of infiltrating CD11b+ cells could 
be appreciated around the tumour vessels, no double positive cells (CD11b+/Nrp-1+) could be 
found in the tested cryo-sections (Figure 21).  
?
?
?
Fig.?20.?T/M?distribution?according? to?VEGF165/VEGF121?ratio? in? ??small?subset?of?newly?collected?
CRC?samples.?None?of?these?samples?showed?high??VEGF165/VEGF121?ratio??
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Fig.?21.?NEMs? are?not? found? in? tumours? that?do?not?up-regulate?VEGF165??Double? immunostaining?against?Nrp-1? and? CD11b?was? performed? in? newly? collected? CRC? frozen? samples.? No? evidence? of? the?presence? of? Neuropilin-1? expressing? bone?marrow-derived?mononuclear? cells?was? found,? as? expected?standing?the?low?expression?levels?of?VEGF165?isoform.??
4.11 Quantification of Sema3A abundance in human CRC 
 To further explore the hypothesis that NEM recruitment contributes to better cancer 
outcome, and based on the fact that Nrp-1 has basically been recognized as a co-receptor for 
Semaphorin3A, in parallel, we evaluated Sema3A expression in the same cohort of patients 
recruited for the VEGF isoform analysis. Noteworthy, Sema3A, similar to VEGF165, has been 
demonstrated to be a potent NEM recruiter (Zacchigna et al., 2008). The obtained cDNAs 
were thus used as templates for real-time PCR amplification to detect the expression levels of 
the Sema3A gene, both in tumours and normal mucosae. For each patient, expression of 
Sema3A was calculated as a ratio between tumour- and mucosa-expressed Sema3A. In the 
whole  data  set,  Sema3A  expression  did  not  show  any  obvious  shift  towards  up-  or  down-
regulation in the tumour mass, with only a modest tendency to down-modulation (Figure 22).  
Nonetheless, in a restricted group of patients (n=8), Sema3A appeared far up- regulated in the 
tumour mass (above 90% CI). Strikingly, these patients (hereinafter referred to as Sema3Ahi) 
had more benign tumours as compared to the remaining patients (hereinafter referred to as 
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Sema3Alow). In particular, as shown in Figures 23 and 24, Sema3Ahi patients  showed  a  
reduced lymph node infiltration, decreased metastatic spread and longer survival (all patients 
are alive 36 months after surgery). Remarkably, these Sema3Ahi tumours showed enhanced 
vessel maturation, as unveiled by vWF/?-SMA double immunostaining (data not shown). 
These data are in perfect concordance with the anti-tumorigenic effect of Sema3A, previously 
observed in tumour xenograft animal models and even more remarkably, with the possibility 
that it might recruit tumour-hampering NEMs also in human malignancies.  
  
Fig.?22.?Distribution?of?accrued?patients?according? to?T/M?ratio?of?
Sema3A? expression.? Tumour? expression? did? not? show? any? tendency?towards? up-? or? down-regulation.? Patients? exceeding? ?? 90%? CI? were?denoted?as?Sema3Ahi?and?labelled?as?red?dots.?Remaining?patients?were?identified?as?Sema3Alow?(black?dots).?Lines?denote?median???90%?CI.?
?
Results 
74?
?
?
?
?
?
?
?
?
?
Fig.?23.?Lymph?node?infiltration?in?Sema3Ahi?patients.?Number?of?positive? lymph? nodes? in? Sema3Ahi? and? Sema3Alow? patients.?Infiltration?was?markedly?reduced?in?the?former?group.?
Fig.?24.?Occurrence?of?distant?metastases?in?Sema3Ahi?and?
Sema3Alow? patients.? Metastasis? positive? patients? were?represented?as?proportion?of? the?entire? subset?of?patients? (in?black?within?white?column?in?the?Figure).??
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????????????Next  we  determined  the  levels  of  Sema3A  expression  in  the  additional  set  of  CRC  
tumours and mucosa pairs (n=30, including the 19 samples described above) for which 
cryopreserved samples were available. Distribution of the results obtained is shown in Figure 
25. Only one of these patients showed a level of expression falling above the 90% CI that was 
considered in the previous experiments, and was thus chosen for further examination. Double 
immunostaining against Nrp-1 and CD11b was performed on 5 µM cryosections of this 
sample. As shown in Figure 26, in this single sample, putative NEMs, defined as double 
positive cells for CD11b and Nrp-1, could be recognized. Their distribution was sparse and 
mostly concentrated in perivascular locations. Of note, double positive cells were evident only 
in this single sample out of 10 tested, out of which the other 9 displayed neither VEGF165 nor 
Sema3A overexpression.  
?
?
?
?
?
?
?
?
?
?
?
?
 
Fig.? 25.?T/M?distribution? according? to? Sema3A? expression? in? newly? collected? CRC? patients.?One?sample?displayed?features?equivalent?to?Sema3Ahi?patients?described?in?Figure?22??and?is?labelled?as???red?dot?in?the?Figure.?
?
? ?
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Fig.? 26.?NEMs? infiltrate? tumours? expressing? high? levels? of? Sema3A.?Detection? of?NEMs? as? double?positive?cells?for?Nrp-1?and?CD11b?antigens.?Immunofluorescence?analysis?showed?the?presence?of?NEMs?(highlighted? by?white? arrows)? in? ?? patient? overexpressing? Sema3A.? Split? signals?were? shown? besides?merged?images.?Gates?(#)?denote?vessels.?Nuclei?were?counterstained?in?blue?with?DAPI.?
?
?
?
?
?
?
?
?
?
?
?
?
?
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4.12 VEGF165/VEGF121 ratio in lung cancer patients 
 Next we became interested in assessing whether our observations in colorectal 
carcinoma had any relevant implication in other human malignancies. For this purpose, thanks 
to a collaboration with the Institute of Genetics and Molecular Oncology (Istituto Oncologico 
Veneto-IRCCS) in Padova, a number of frozen lung cancer specimens were collected (n=42). 
The expression levels of VEGF165 and  VEGF121 isoforms were measured employing the 
approaches described in Chapter 3. As shown in Figure 27,  the  VEGF165/VEGF121 ratio 
showed a wide distribution also in this sample set (mean value=0.27±0.16). In the case of 
lung  carcinoma,  the  expression  level  of  VEGF121 was  consistently  higher  than  that  of  
VEGF165. Furthermore, a restricted subset of patients displayed a significantly increased 
VEGF165/VEGF121 ratio (above 90% C.I.). Similar to the case of colorectal carcinoma, in lung 
cancer patients with the higher expression level of VEGF165 (VEGF165hi), no lymph node 
infiltration was detected (Figure 28).   
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Fig.? 27.? VEGF? isoforms? in? lung? cancer.? In? ?? cohort? of? lung? cancer? patients,?VEGF165/VEGF121? ratio? was? measured.? This? ratio? demonstrates? ?? broad? distribution?among?the?patients?and?similar?to?the?cohort?of?colorectal?cancer?patients,?again???small?subset?of?the?patients?shows?higher?level?of?expression?of?VEGF165??
Fig.?28.?Number?of?positive?lymph?nodes?in?VEGF165int??VEGF165hi?
and?VEGF121hi?lung?cancer?patients.?
Results 
79?
?
4.13 Analysis of Sema3A expression in the same set of lung cancer patients 
 Normalized Sema3A expression (over GAPDH) in the same cohort of lung cancer 
patients was also assessed by quantitative PCR approach. Sema3A expression was then 
plotted as in Figure 29, again unveiling a restricted number of the patients (4 out of 40) who 
expressed tumour levels of Sema3A significantly above average (exceeding 90% C.I.). 
Amongst these samples, one (ACP29) showed up-regulation in both VEGF165 content and 
Sema3A expression.  
 
??
?
?
?
?
?
?
?
?
?
?
?
?
?
4.14 Hypoxia induces specific VEGF165 up-regulation   
 As previously mentioned, three distinct biopsies (from the healthy mucosa, periphery 
and core of the lesion) was collected in a small subset of the CRC patients (n=19). It is widely 
recognized that the marginal (“periphery”) and the central (“core”) areas of a tumour mass 
possess clearly distinct features, at both structural and molecular level. To assess whether 
these differences affect VEGF165/VEGF121 ratio, standard isoform quantification was applied 
to this restricted set of samples. 
Fig.? 29.? T/M? distribution? of? lung? cancer?
patients?according?to?Sema3A?expression.?
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 The VEGF165/VEGF121 ratio was consistently up-regulated in the core of the lesion 
compared to the periphery and mucosa samples of the same patients. As shown in Figure 30, 
VEGF165/VEGF121 ratio in mucosa displayed a significant degree of homogeneity, being most 
samples gathered close to an average value of 0.53±0.12 (23% Coefficient of Variation). The 
average value of VEGF165/VEGF121 ratio was increasingly higher in the periphery and the 
core of the tumour (0.61±0.19 and 0.66±0.2, respectively). Heterogeneity was also increased 
in tumour datasets (both in periphery and core), displaying 32% and 37% as Coefficient of 
Variation, respectively. 
Once more, these data demonstrate that malignant transformation has a profound 
impact on VEGF-A alternative splicing regulation. Progression towards a less structured, less 
vascularised and more chaotic area of tumour mass consistently entails an up-regulation of 
VEGF165. 
It is generally conceived that the most interior part of the tumour mass is more 
hypoxic. Due to poor and inefficient vascularization in the core of the tumour, it was 
originally envisaged that hypoxia might induce a specific preference for VEGF165, an isoform 
specifically involved in vessel maturation as widely discussed throughout this thesis.  
This issue was further investigated to unveil the molecular events leading to VEGF 
isoform selection in a highly hypoxic environment. 
?
?
?
?
?
?
?
?
?
?
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Fig.? 30.? VEGF? splicing? depends? on? local?
environment.? VEGF165/VEGF121? ratio? was?evaluated? in? normal? epithelial? tissue? (mucosa,?light? grey? dots),? border? of? tumour? mass?(periphery,? dark? grey? dots)? and? interior? of?tumour?mass?(core,?black?dots).?Horizontal?lines?denote? mean? ?? s.e.m.? Progressive? increase? in?VEGF165/VEGF121?ratio?was?observed.??
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4.15 Effect of hypoxia on the expression levels of VEGF-A isoforms in different tumour 
cell lines 
 In order to assess the putative impact of low oxygen tensions on VEGF-A alternative 
splicing,  two  sets  of  experiments  were  performed.  In  a  preliminary  experiment,  in  order  to  
create a hypoxic environment, a classic hypoxic chamber was employed. Two different cell 
lines (4T1 breast carcinoma and HUVEC endothelial cells) were subjected to a strong hypoxic 
conditioning for 2 or 24 hours. Wild-type cells were maintained in normoxia for the duration 
of the experiment. Then, using TRIzol, the RNA was extracted and, after cDNA preparation, 
the VEGF165/VEGF121 ratio was quantified. In fact, prolonged hypoxia conditioning induced 
the up-regulation of VEGF165 in  a  time  dependent  manner  in  both  cases,  whereas  VEGF121 
expression was not significantly affected, as shown in Figure 31.  
 Noteworthy, the above described experiment was performed exploiting an old hypoxic 
chamber that essentially creates an anoxic environment, using N2 to replace O2 into the 
chamber. This represents a largely non physiological condition, thus a further experiment was 
performed employing an advanced hypoxia incubator chamber, in which the concentration of 
CO2 and N2 was finely tuned during the experiment’s duration. In this respect, three various 
tumour cell lines were employed; T241 (fibrosarcoma), 4T1 (breast carcinoma), and B16-F10 
(melanoma). Cells were exposed to hypoxia conditioning (1% O2 tension), for 2 and 18 hours. 
Isoform quantification analysis revealed that, in all three conditions, VEGF165 was the 
preferred isoform compared to the shorter isoform, and that hypoxia significantly increased 
the isoform balance towards VEGF165 (Figure 32).  
 Both experiments clearly demonstrated that malignant cells respond to hypoxia by 
altering the balance between VEGF isoforms, preferentially producing VEGF165. This effect is 
consistent in all tumour cell lines tested so far, but its kinetic and magnitude vary 
significantly. The reason for this variability is currently under investigation; upon hypoxic 
conditioning, the HIF pathway was equally activated in all three cell lines, as revealed by 
negative feedback regulation of HIF-1? mRNA and shown in Figure 33. Similarly, VEGF-A 
total mRNA was equally up-regulated in all cases (data not shown).  
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Fig.? 31.? Hypoxia? and? VEGF? splicing.? 4T1? (breast? cancer)? and? HUVEC?(endothelial)? cell? lines?were? exposed? to? hypoxic? conditioning? for? ?? and? 24?hours?using???routine?hypoxic?chamber.??VEGF165/VEGF121?ratio?was?assessed?by? PCR? approach:? gel? electrophoresis? results? are? shown? on? the? right.?Quantifications?are?shown?on? the? left?as?column?graphs.?Noticeable? increase?was?observed?upon?severe?hypoxic?conditioning.?
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Fig.? ?32.?Hypoxia?affects?VEGF?splicing.?Using? ??hypoxia? incubator? chamber,?various?cancer? cell? lines?were?exposed?to?hypoxia?to?assess?the?effect?of?low?oxygen?levels?on?the?regulation?of?alternative?splicing?of? VEGF? isoforms? in? ?? time-dependent? manner.? As? ?? control,? cells? were? cultured? under? normoxia?condition.?In?the?case?of?T241?cell?line,?the?expression?level?of?VEGF165?was?clearly?increased?after?18?hours?of? hypoxia? conditioning.? B16-F10? cell? line? shows? up-regulation? of? VEGF165? but? in? ?? slightly? different?manner.?As? evident? in? the? gel? image,? VEGF165? has? been? overexpressed? during? hypoxia? exposure? time,?however,?based?on?band?quantification?data,?visible?switching?towards?VEGF165?up-regulation?might?need?longer? than?18?hours?of?exposure? to?hypoxia.?Instead,? in?4T1?cell? line,?based?on? the?band?quantification?analysis,?this?continuous?modulation?towards?the?overexpression?of?VEGF165?was?evident.?
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Fig.? 33.?HIF-?? is? negatively? regulated? upon? hypoxic? conditioning.?Using?Real-? Time? PCR?approach,? the? effect? of? hypoxia? on? the? expression? of? HIF-1?? was? assessed? in? three?aforementioned?cancer?cell?lines.?In?fact,?under?prolonged?hypoxia,?all?three?cell?lines?showed???HIF-1??negative?feedback?in?response?to?hypoxia?in???time-dependent?manner.?
?
?
?
?
?
?
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?
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5. DISCUSSION 
The  project  described  in  this  thesis  primarily  examines  the  balance  of  the  two  most  
expressed splicing isoforms of VEGF-A, specifically VEGF165 and VEGF121, on the 
pathology  of  CRC.  In  our  study,  CRC  was  considered  as  an  example  of  pathological  
angiogenesis and used to assess the specific roles of two isoforms of VEGF-A, certainly the 
best characterized among the several of pro-angiogenic factors known.  
Indeed, VEGF165 and VEGF121 have well-recognized different biological properties. 
Most notably, VEGF121 is freely diffusible in the extracellular matrix, whereas the longer 
isoform is more strongly bound to the extracellular matrix, and released upon enzymatic 
digestion of ECM components by metalloproteinases. In addition, VEGF165 and  VEGF121 
differ in their capacity to bind Neuropilin-1 (Nrp-1), an important co-receptor able to enhance 
VEGF-A binding to canonical receptors. Consistently, compelling evidence now suggests that 
VEGF165 and VEGF121 in fact elicit significantly different angiogenic response in vivo, in 
terms of magnitude, vessel structure, kinetic and functional outcome. We thus wondered 
whether tumours might preferential express one specific isoform to sustain the highly atypical 
vascularization that invariably distinguishes all solid tumours. To tackle this issue, 78 CRC 
patients were recruited in this study and, at the moment of therapeutic surgical resection, a 
biopsy of tumour mass was dedicated to RNA analysis.  Similarly,  for each patient,  a paired 
sample of normal, healthy mucosa was collected. VEGF165 and VEGF121 relative abundance 
was evaluated in tumour and matched mucosa samples. No clear tendency toward up-
regulation of either isoforms could be detected. A striking variability in isoform balance was 
observed: VEGF165/VEGF121 ratio was decreased impaired in the malignant tissue in the vast 
majority of the samples. Alteration in VEGF splicing balance was appreciable in a significant 
number of patients, although the relevance of this phenomenon for cancer biology and 
progression remains somehow elusive.  
Others have described increased VEGF121 expression in bladder cancer (Catena et al., 
2007), an event associated with enhanced angiogenesis and worse outcome. Previous 
experiments performed at the Molecular Medicine Laboratory on xenotransplanted tumour 
models, suggest that conditioning the microenvironment with VEGF121 results in accelerated 
tumour growth. More remarkably, VEGF165-conditioning significantly inhibits tumour 
growth,  consistent  with  a  specific  anti-tumour  activity  of  VEGF165. Importantly, such 
inhibitory activity is due to a modification of the local microenvironment, notwithstanding the 
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potent pro-angiogenic activity of all VEGF-A isoforms. This in fact, unravels a level of 
complexity in VEGF biology.  
In  CRC  samples,  VEGF121 was invariably found to be more expressed compared to 
VEGF165, both in tumours and mucosa samples, contrary to the general assumption that 
considers the latter the most abundant VEGF-A isoform in vertebrates. Whether this feature 
reflects a tissue-specific characteristic or underpins a sort of predisposition in individuals who 
will develop CRC, is probably worth further investigations. 
We assessed the correlation between tumour grading (G) and the relevant 
VEGF165/VEGF121 ratio, both in the mucosa and tumour samples of the CRC specimens 
studied during this project. Although not statistically significant, for the patients for whom 
clinical data were available, we observed that the VEGF165/VEGF121 ratio was higher in both 
mucosae and tumour counterparts of the samples belonging to the patients categorized with 
the low grading level (a distinction that joins in the same category G= 0 and G= 1 patients). 
Conversely, in the samples with grading levels evaluated as 2 and 3 (intermediate and high), 
VEGF165/VEGF121 ratio was reduced. This finding might suggest an inverse correlation 
between tumour grading and VEGF165 expression. In addition, in patients displaying a lower 
tumour grade, the expression level of VEGF165 was higher in both tumour and its 
corresponding mucosa. In higher levels of grading, cells are morphologically very abnormal 
and poorly differentiated; they grow more quickly, and they may metastasize easily 
(www.cancer.gov). In this case, the VEGF165/ VEGF121 ratio resulted decreased in both 
tumour and matched mucosa, consistent with a possible role of VEGF121 in promoting tumour 
progression. Due to the high variability of the results, it is unlikely that the determination of 
VEGF121 levels might possess prognostic or predictive value, however it appears important to 
unravel the molecular mechanisms of tumour growth and local invasion.  
Considering metastasis as another important clinical feature in the context of CRC, we 
compared VEGF165/VEGF121 ratio in mucosa and tumour samples of each CRC patient with 
or without metastasis (M) occurrence. In this regard, total VEGF165/VEGF121 ratio in tumour 
vs. mucosa of metastasis negative (M-) patients was evidently lower than in the patients with 
the occurrence of metastasis. Since VEGF165 promotes vessel normalization, this observation 
appears to be in line with recent findings indicating that the presence of a more mature 
vascular network, while decreasing tumour growth, on the contrary increases the propensity to 
metastatic spread. In particular, this was highlighted by recent observations in patients who 
received anti-angiogenic treatment (Loges et al., 2009). As a result of vascular normalization, 
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it is plausible that cancer stem cells or metastatic cancer cells have the opportunity to enter the 
blood circulation through large, mature blood vessels, carrying a regular flow, rather than 
exploiting small, narrow, stagnant branches of a disorganized vascular network. Noteworthy, 
extravasation  of  cancer  cells  invariably  requires  physical  endorsement  at  the  level  of  
extracellular matrix, which works as tracks for spreading cells. In this respect, mature vessels, 
sheathed with more structured ECM components, might represent a more suitable route for 
invasion (Naito et al., 2012).  
Not taking into account the concept of vessel normalization, it might more simply be 
speculated that the overexpression of VEGF165 might favour metastasis through different 
mechanisms. Accordingly, it has been recently demonstrated that VEGF acts as a negative 
regulator of pericytes (Greenberg et al., 2008). We have also previously reported the 
formation of aberrant vascular structures upon AAV-mediated overexpression of VEGF165 
(Zacchigna et al., 2007). 
At a closer look, examining the VEGF isoform balance, uniquely in mucosa samples, 
it was clearly evident that the VEGF165/VEGF121 ratio in the normal tissue of metastatic (M+) 
CRC patients was markedly lower when compared to the equally “normal” tissue of non-
metastatic (M-)  patients.  Indeed,  the  VEGF165/VEGF121 ratio was substantially comparable 
when comparing the two datasets relative to M+ and M- tumours. This finding raises the 
intriguing possibility that high VEGF121 expression sets a predisposition in normal epithelial 
tissues towards the development of highly metastatic malignant diseases. This hypothesis is 
consistent with the superior tumorigenic potential of VEGF121 revealed by tumour 
xenotransplantation experiments in mouse models (Carrer et al., submitted).  
 One of the most recent, novel findings of our laboratory was the detection of a unique 
population of bone marrow-derived myeloid cells mobilized to the site of human tumour 
malignancies through VEGF165 expression. These cells (Neuropilin-1 Expressing Monocytes, 
NEMs) are characterized as a subset of CD11b+Nrp1+Gr1- myeloid cells. By attracting NEMs, 
VEGF165 induces the pericyte coverage of the newly-formed blood vessels (Zacchigna et al., 
2008). NEMs secrete a broad range of cytokines and growth factors involved in the 
recruitment of mural cells (pericytes and vascular smooth muscle cells) to nascent blood 
vessels. This phenomenon plays a crucial part in the stabilization and maturation of new 
vascular network.   
To understand whether VEGF165 retains the above described properties also in the 
context of human malignancies, we identified a small subset of the patients (n=6) who 
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expressed particularly high levels of VEGF165. We compared vascular morphology in such 
tumours with the one present in tumours showing a singularly reduced VEGF165/VEGF121 
ratio. Interestingly, no sign of lymph node infiltration was detectable in the VEGF165hi 
patients, consistent with a protective role of this longer VEGF isoform. Moreover, 
immunofluorescent analyses of the tumour samples belonging to this subset of the patients 
revealed that their vessels were covered with an increased number of ?-SMA+ cells; unveiling 
the more mature structure of the vascular network in tumours specifically expressing high 
levels of VEGF165.  
It  was  not  possible  to  assess  the  presence  of  Nrp-1+ myeloid cells in VEGF165hi 
tumours, due to technical reasons. Hence, the question whether NEM recruitment in fact 
accounts for blood vessel maturation in those tumours still remains unresolved. More 
interestingly, with respect of metastasis, our data might imply that NEM recruitment indeed 
favour invasiveness, as many other tumour-infiltrating myeloid cells. 
Very similar to the case of AAV-mediated delivery of VEGF165, massive cellular 
infiltration of NEMs was also promoted by AAV-Sema3A injection in the mouse skeletal 
muscle (Zacchigna et al., 2008). Hence, we wondered whether the same effects on the 
maturation of tumour vessels could be observed as a consequence of the spontaneous Sema3A 
overexpression in tumour masses. A small group of patients bore tumours that overexpressed 
Sema3A. Remarkably, these Sema3Ahi patients displayed improved clinical outcome and 
longer survival and their tumours exhibited a more mature vascular network, as unveiled by 
immunofluorescence analysis. In a set of recently collected frozen samples of CRC patients 
(none of which up-regulating VEGF165),  the  presence  of  NEMs  as  CD11b+/Nrp-1+ myeloid 
cells could also be assessed in patients overexpressing Sema3A. This represents the first 
evidence of the presence of NEMs at the site of angiogenesis in human malignancies. 
Another  section  of  this  study  was  dedicated  to  evaluate  the  effect  of  hypoxia  on  the  
splicing regulation of VEGF-A in vitro. Since the cores of the CRC lesions were reasonably 
more  hypoxic,  we  wondered  whether  this  condition  might  affect  the  regulation  of  VEGF165 
isoform production. In particular, arising from the observation that the VEGF165/VEGF121 
ratio was increased in the core of the tumour samples, we hypothesized that environmental 
stresses might favour the selection of the longer isoform. Thus, a set of hypoxic conditioning 
experiments using different cell lines (including endothelial and tumour cell lines) was 
performed. Collectively, the results of these experiments revealed that hypoxic conditioning 
up-regulated the levels of VEGF165 in a time-dependent manner. VEGF165 up-regulation could 
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be conceived as the result of massive HIF-1? activity likely established in hypoxic, poorly 
vascularised tumours. There might be a strict link between this finding and the observation 
that the tumours with higher levels of VEGF165 are more prone to metastasize, since HIF-1? 
loss-of-function results in decreased tumour growth, vascularization and invasiveness (Du et 
al., 2008; Lee et al., 2009a; Lee et al., 2009b; Liao and Johnson, 2007; Maxwell et al., 1997; 
Ryan et al., 1998; Stoeltzing et al., 2004). Further experiments are clearly needed to further 
address this issue and define the molecular mechanisms linking hypoxia, HIF-1 up-regulation 
and the regulation of VEGF precursor RNA splicing.  
Taken together, the results of this thesis demonstrate that the modulation of VEGF 
splicing  is  a  very  complex  process,  which  ultimately  affects  several  aspects  of  tumour  cell  
biology. The different VEGF isoforms modulate the tumour microenvironment by both 
directly influencing tumour vessel formation and by stimulating the tumour infiltration by 
specific circulating cell populations. A better understanding of the factors affecting VEGF 
pre-mRNA processing is required to shed light into this intricate network of interactions. 
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